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Regulation of Secretory Phospholipase A2 by Thyroid Hormone
Abstract
Rationale: Low grade inflammation has been correlated with elevated risk of hepatic steatosis and
atherosclerosis. Secretory phospholipase A2 group IIA (PLA2g2a) enhances the progression of several
chronic inflammatory diseases including arthritis and atherosclerosis. The potential linkage of
hypothyroidism with inflammation led us to examine the modulation of sPLA2 expression by thyroid
hormone (T3) in liver.
Objective: Most of the studies of phospholipase A2 group IIA (PLA2g2a) have been conducted with
macrophages and vascular smooth muscle cells with regard to atherosclerosis. The liver is one of the
major contributors to the total pool of extracellular PLA2g2a. The aim of the present study was to
characterize the regulation of PLA2g2a and other sPLA2 genes by T3 in liver. The second aim was to
identify the mechanism by which T3 inhibits the expression of PLA2g2a gene.
Methods and Results: In the first part of my project, I assessed the effect of T3 on sPLA2 gene expression
in liver. I found that T3 inhibited the expression of the PLA2g2a in human and rat hepatocytes. Thyroid
hormone status regulated the expression of endogenous PLA2g2a in both rats and mice. Other sPLA2
isoforms including PLA2g1b, PLA2g3 and PLA2g5 were also suppressed by T3 in liver. PLA2g2a was
induced by cytokines and high fat diet. Both the cytokine and fatty acid mediated induction of PLA2g2a
gene was blocked by T3. In an effort to dissect the mechanism of repression by T3, I cloned the PLA2g2a
gene and identified a negative T3 response element in the promoter. This thyroid receptor (TRβ) binding
site differs considerably from consensus T3 stimulatory elements. Using in vitro and in vivo binding
assays, I demonstrated that TRβ bound directly to the PLA2g2a promoter. In present studies, I found that
disruption of the corepressor binding site in TRβ decreased the T3 inhibition of PLA2g2a. Conversely a
mutation in coactivator binding site had no effect on the T3 mediated inhibition of PLA2g2a. Knockdown
of nuclear corepressor (NCoR1) or silencing mediator for retinoid and thyroid receptors (SMRT) by siRNA
blocked the T3 inhibition of PLA2g2a. Using chromatin immunoprecipitation assays, I showed that NCoR1
and SMRT were associated with the PLA2g2a gene in the presence of T3.
Conclusion: The thyroid hormone status modulates the expression of PLA2g2a and other sPLA2
isoforms. Both hyperthyroid rats and mice had significantly lower levels of PLA2g2a as compared to
hypothyroid rats and mice. My data suggest that the thyroid status modulates aspects of the
inflammatory response. In contrast with the established role of T3 to recruit coactivators to TRβ, my
experiments demonstrate a novel inverse recruitment mechanism in which unliganded TRβ is stimulatory
while liganded TRβ recruits corepressors to inhibit PLA2g2a expression. In conclusion, present study
provides a cellular mechanism by which T3 inhibits PLA2g2a expression.
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ABSTRACT
Rationale: Low grade inflammation has been correlated with elevated risk of hepatic
steatosis and atherosclerosis. Secretory phospholipase A2 group IIA (PLA2g2a) enhances
the progression of several chronic inflammatory diseases including arthritis and
atherosclerosis. The potential linkage of hypothyroidism with inflammation led us to
examine the modulation of sPLA2 expression by thyroid hormone (T3) in liver.
Objective: Most of the studies of phospholipase A2 group IIA (PLA2g2a) have been
conducted with macrophages and vascular smooth muscle cells with regard to
atherosclerosis. The liver is one of the major contributors to the total pool of extracellular
PLA2g2a. The aim of the present study was to characterize the regulation of PLA2g2a
and other sPLA2 genes by T3 in liver. The second aim was to identify the mechanism by
which T3 inhibits the expression of PLA2g2a gene.
Methods and Results: In the first part of my project, I assessed the effect of T3 on
sPLA2 gene expression in liver. I found that T3 inhibited the expression of the PLA2g2a
in human and rat hepatocytes. Thyroid hormone status regulated the expression of
endogenous PLA2g2a in both rats and mice. Other sPLA2 isoforms including PLA2g1b,
PLA2g3 and PLA2g5 were also suppressed by T3 in liver. PLA2g2a was induced by
cytokines and high fat diet. Both the cytokine and fatty acid mediated induction of
PLA2g2a gene was blocked by T3. In an effort to dissect the mechanism of repression by
T3, I cloned the PLA2g2a gene and identified a negative T3 response element in the
promoter. This thyroid receptor (TRβ) binding site differs considerably from consensus
T3 stimulatory elements. Using in vitro and in vivo binding assays, I demonstrated that
TRβ bound directly to the PLA2g2a promoter. In present studies, I found that disruption
of the corepressor binding site in TRβ decreased the T3 inhibition of PLA2g2a.
Conversely a mutation in coactivator binding site had no effect on the T3 mediated
inhibition of PLA2g2a. Knockdown of nuclear corepressor (NCoR1) or silencing
mediator for retinoid and thyroid receptors (SMRT) by siRNA blocked the T3 inhibition
of PLA2g2a. Using chromatin immunoprecipitation assays, I showed that NCoR1 and
SMRT were associated with the PLA2g2a gene in the presence of T3.
Conclusion: The thyroid hormone status modulates the expression of PLA2g2a and other
sPLA2 isoforms. Both hyperthyroid rats and mice had significantly lower levels of
PLA2g2a as compared to hypothyroid rats and mice. My data suggest that the thyroid
status modulates aspects of the inflammatory response. In contrast with the established
role of T3 to recruit coactivators to TRβ, my experiments demonstrate a novel inverse
recruitment mechanism in which unliganded TRβ is stimulatory while liganded TRβ
recruits corepressors to inhibit PLA2g2a expression. In conclusion, present study
provides a cellular mechanism by which T3 inhibits PLA2g2a expression.
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CHAPTER 1.

INTRODUCTION

General Biology
The purpose of this chapter is to review the background information relevant to
the research reported in the dissertation. These topics include thyroid hormone biology,
thyroid hormone receptors types, coregulator proteins and the mechanisms of positive
and negative gene regulation by thyroid hormone. Finally, a general overview of
secretory phospholipases is provided.
Thyroid hormone (T3) is secreted by the follicular cells of the thyroid gland. T3
(L-3, 5, 3-tri-iodothryronine) is the derivative of the amino acid tyrosine, consisting of
two tyrosine moieties covalently attached to iodine. There are two major forms of the
thyroid hormone thyroxine (T4) and T3. T3 is the active form of thyroid hormone and is
formed by the deiodination of T4 by type I and type II deiodinase enzymes (Oetting &
Yen, 2007; Yen, 2001). Recent studies have found that rT3, T2 and other deiodinated
thyroid derivatives have biologic activity (Moreno et al 2008). The structures of T3 and
T4 are shown in Figure 1-1.
Modular Structure of Thyroid Hormone Receptor
The thyroid hormone receptor (TR) belongs to a family of nuclear receptors (NR).
NRs are ligand dependent transcription factors which control gene transcription in
response to hormone binding. The NR family is the largest family of transcriptional
regulators consisting of 48 members in human. This superfamily serves as receptors for
various lipophilic molecules including steroid hormones (estrogen, testosterone,
glucocorticoids, mineralocorticoid, and vitamin D), thyroid hormone, retinoic acid, fatty
acids and others. The TR and other nuclear receptors share similar functional domains
(Steinmetz et al, 2001). As shown in Figure 1-2, the TR consists of four main domains:
N-Terminal A/B Domain
A/B is the most variable region among the TR isoforms in terms of the amino acid
sequence and length. A constitutively active domain (AF-1) resides in A/B domain. AF-1
functions in a gene and cell specific manner. The role of the A/B domain in
transcriptional activation by TRs is controversial.
DNA-Binding Domain (DBD)
The DBD is the most conserved domain of TRs. It is involved in identification
and binding of TR to the thyroid response element. This region is located in the central
portion of TR and is 66 amino acids long. It consists of two zinc fingers each containing
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Structure of thyroid hormone

The thyroid hormone are basically two tyrosine moieties linked together with the addition
of iodine at three or four positions. Different forms of thyroid hormones including T4, T3,
and reverse T3 are generated based on the number and position of the iodine group.

Figure 1-2.

Modular structure of thyroid hormone receptor

TR is divided into four major region Activation function -1(A/B) domain, DNA binding
domain (DBD), hinge region and Ligand binding domain (LBD).
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four cysteines coordinated with Zn2+ ion. Within the first Zn finger there is P box, which
is responsible for the identification of the thyroid response element. The D box located in
the second Zn finger contributes to the dimerization of TR. TR generally binds as
heterodimer with retinoic acid X receptor (RXR).
Hinge Region
Hinge region lies between the DBD and the ligand binding domain and provides
flexibility to TR. This region is rich in the amino acid lysine. The Hinge region interacts
with various corepressors including the nuclear corepressor (NCoR1) and the silencing
mediator of retinoid and TR (SMRT). This region also has nuclear localization signals for
TR.
Ligand-Binding Domain (LBD)
The LBD is located in the C terminal region and consists of approximately 250
amino acids. This domain is critical for T3 binding. It is responsible for the unliganded
TR mediated repression of gene expression as well as T3 dependent gene activation. The
LBD is comprised of 12 alpha helices which form a pocket for T3 binding. Binding of T3
to TR causes a conformational change in helix 12 which contains the activation function2 (AF-2) domain. The AF-2 domain interacts with co-activators in a ligand dependent
manner.
Thyroid Hormone Receptor Types
Thyroid receptor has two major types TRα and TRβ. These two isoforms of TR
are encoded by two different genes located on chromosomes 3 and 17 respectively
(Cheng et al, 2010a).
TRα Receptor
The TRα gene encodes for T3 receptor α1 and a C terminal splice variant TRα2.
TRα2 differs from TRα1 in length and the sequence of amino acids in the C terminal
region. The TRα2 variant cannot bind T3 but it retains its DNA binding ability. It
antagonizes the T3 mediated action of TRα, TRβ1 and TRβ2 (Koenig et al, 1989;
Plateroti et al, 2001). The TRα1 and TRα2 are expressed in brain, kidney, skeletal
muscles, lungs, heart. The actions of T3 in heart are mediated, primarily by the TRα1
isoform.
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TRβ Receptor
TRβ has 3 isoforms TRβ1, TRβ2 and TRβ3. The TRβ1 is highly expressed in
brain, liver, and kidney. TRβ2 is expressed in pituitary, hypothalamus, and inner ear
while TRβ3 is predominantly expressed in kidney, liver and lungs. The actions of T3 in
liver are mediated by TRβ1 isoform. All three isoforms of TRβ are functionally active.
Coregulators
Thyroid hormone regulates gene transcription by the interaction of TR with other
regulatory proteins. Coregulator proteins often act as a docking scaffold for other proteins
like histone deacetylases (HDACs) and histone acetyl transferases (HATs). Coregulator
proteins depending up on whether they promote or inhibit transcription are divided into
coactivator and corepressors respectively.
Corepressors
In absence of T3 unliganded TR binds DNA and represses the transcription of
positively regulated target genes. This basal repression by unliganded TR is mediated by
NCoR1and SMRT along with histone deacetylases (HDACs).
SMRT and NCoR1. SMRT and NCoR1 were the first two corepressors identified
for nuclear receptors. SMRT and NCoR1 are structurally and functionally related. As
shown in Figure 1-3, these corepressors can be divided into an N terminal region having
3-4 transcriptional repression (RD) domains and a C terminal region having 2-3 nuclear
receptor interaction domains (Li et al). NCoR1 and SMRT serve as an adapter between
the corepressor complex and nuclear receptors.
The repression domain (RD). The RD serves as a docking site for the various
other components of the corepressors complex, including HDACs, transducing like
protein 1(TBL-1) and mSin3 and sirtuin 1 (SIRT1). Antibodies blocking of each of the
component of NCoR1-SMRT-Sin3-HDAC complex relieve the repression by unliganded
TR suggesting that each component is crucial for repression.
Switching-defective protein 3 (Swi3), adaptor 2 (Ada2), nuclear receptor
co-repressor (N-CoR), transcription factor (SANT) like domain. The SANT domain is a
50 amino acid motif present in nuclear corepressors. Both NCoR1 and SMRT contain a
pair of closely related SANT domains. This domain along with RD synergistically
promotes histone decetylation. The binding of NCoR1 and SMRT to HDAC3 is
necessary to form active repressor complexes. SANT 1 domains comprise a part of the
deacetylases interacting domain (DAD) responsible for interaction of SMRT and NCoR1
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Figure 1-3.

Structural organization of NCoR1

The modular structure of NCoR1 is depicted in the figure. It consists of three repression
domains (RID) and three nuclear receptor interaction domains (RID). The sites of
interaction of other components of the corepressor complex are shown.
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with HDAC3. A single amino acid change in SANT A domain disrupts the binding of
NCoR1 and SMRT with HDAC3. The SANT B domain is known to function as histone
interaction domain.
Receptor-interaction domain (RID). The RID consists of signature motif L/I-XX-I/V-I known as CoR-nuclear receptor interaction box (CORNR) through which NCoR1
and SMRT interact with nuclear receptors. SMRT contains two while NCoR1 contains
three RID. TR interacts with RID3 and RID2 domains of NCoR1 with high affinity, and
with low affinity to the RID2 and RID1 of SMRT. The CORNR box forms an extended
alpha helical domain that interacts with the helices 4/5/6 of the nuclear receptor ligand
binding domain.
Histone deacetylases (HDACs). Transcriptional regulation is dependent on the
structure of the chromatin and the binding of the transcription factors and transcriptional
machinery to the promoter of genes. DNA is wrapped around histones H2A, H2B, H3
and H4 to form nucleosomes which are the fundamental unit of chromatin. The histones
in the nucleosomes undergo various post- translational modifications and thereby modify
the chromatin structure. In general deacetylation of lysine residues of histone tails is
associated with condensed chromatin and gene silencing (Kuo & Allis, 1998; Ng & Bird,
2000).
HDACs are enzymes which deacetylate (Figure 1-4) the lysine residues of
histone tails. Removal of the acetyl group from the histone tails results in tighter binding
of the negatively charged DNA around the positively charged lysine residues of histones
leading to the formation of heterochromatin. Tighter wrapping of DNA diminishes the
accessibility of transcription factors leading to gene silencing. Other than histone tails,
HDACs can deacetylate various transcription factors like p53, GATA-1 etc.
HDACs are recruited to TR in a complex with NCoR1 and SMRT. For its
deacetylase activity, HDAC3 needs to interact with NCoR1 and SMRT. HDAC3 is one
of the major enzymes associated with NCoR1 and SMRT. The HDAC family consists of
18 genes which are further divided into four major categories (de Ruijter et al, 2003; Witt
et al, 2009).
Class I HDACs. This class includes HDACs 1, 2, 3 and 8. Members of this class
are found exclusively in nucleus. They are involved in transcriptional repression by
nuclear receptors. HDAC 1, 2 and 3 by themselves are not active. They require other
proteins which are necessary for their deacetylase activity and DNA association. For
example HDAC1 and HDAC2 are found in complex with Sin 3 and NuRD. Similarly
HDAC3 is found in complex with NCoR1/SMRT.
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Figure 1-4. Histone tail modification catalyzed by histone acetylases and
deacetylases
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Class II HDACs. This class is further subdivided into type IIa and IIb. Class II
HDACs are located in both nucleus and cytoplasm. Class IIa includes HDAC 4, 5, 7
and 9 while class IIb includes HDAC 6. Class IIa HDACs interact with myosin
interacting factor, Ca2+/ calmodulin dependent kinases and protein kinase D. On the other
hand HDAC 6 interacts with α-tubulin and HSP 90 dependent kinases.
Class III HDACs. Sirtuins belongs to class III HDACs and there are seven
members of sirtuins (Sirtuin1-7) in this class. These are NAD+ -dependent histone
deacetylases. Sirtuin 1, 6 and 7 are found in nucleus, sirtuin 3, 4 and 5 are located in
mitochondria while sirtuin 2 is located in cytoplasm (Kim & Bae, 2011).
Class IV HDACs. HDAC 11 is the sole member of this group and is closely
related to HDAC 3 and 8. The function and expression patterns of HDAC 11 had not
been investigated extensively.
Other corepressors. Other proteins in the corepressors complex include Sin3,
transducing like protein 1 (TBL-1) and TBL-1 related protein (TBL-R). These proteins
make additional contacts with HDACs and stabilize the corepressor complex formation.
Coactivators
Coactivators are usually associated with the ligand bound nuclear receptors and
are responsible for enhancing the gene transcription. Coactivators can stimulate gene
transcription by various methods. In order to facilitate the binding of basal transcription
machinery and transcription factors to chromosomal DNA, coactivators mediate multiple
chromatin modifications. Coactivators are broadly classified into following categories
(McKenna & O'Malley, 2002; Rachez et al, 1998):
ATP-dependent chromatin remodeling complexes. In order to facilitate
transcription, the binding of basal transcription machinery and general transcription
factors to the promoter is necessary. This class of ATP-dependent chromatin remodeling
complex utilizes the energy derived from the hydrolysis of ATP to destabilize and
displace histone DNA interactions. Examples of this class include SWI/SNF complexes
(Laurent et al, 1993).
Histone acetyl transferases (HATs). This class containing the Steroid receptor
coactivator (SRC) /p160 family includes SRC-1, glucocorticoid receptor interacting
protein (GRIP/SRC-2), P300/ cAMP response element binding protein and the P300
associated factor (PCAF). Members of this family have intrinsic histone acetylase
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activity. These coactivators acetylate lysine residues of histones which in turn serve as a
signal for transcriptional activation (Naar et al, 2001).
Mediator complex. The mediator complex was simultaneously identified as
thyroid receptor associated proteins (TRAPs) and vitamin D receptor interacting protein
(DRIP). These complexes were initially purified as proteins recruited by thyroid hormone
receptor and vitamin D receptor (Fondell et al, 1996; Rachez et al, 1998). This complex is
known to promote and stabilize the formation of pre-initiation complex. It helps in
recruiting the basal transcription machinery and RNA polymerase II to the promoter
(Roeder, 2005).
Regulation of Gene Expression by Thyroid Hormone
Thyroid hormone regulates expression of genes involved in various processes like
gluconeogenesis, fatty acid oxidation, lipogenesis cell proliferation and apoptosis. By
binding to the thyroid response element (TRE), the TR can either activate or repress the
transcriptional activity (Lazar, 2003). Examples of both positively and negatively
regulated genes by T3 are mentioned in Table 1-1.
Thyroid Response Elements (TRE)
TR regulates gene expression by directly binding to specific DNA sequence
known as thyroid response elements (TRE) present in the promoter of genes regulated by
T3. TR binds to TRE either as a monomer, homodimer or as a heterodimer with retinoic
X receptor (RXR). RXR is the dimerization partner for retinoic acid receptor (RAR),
vitamin D receptor (VDR) and peroxisome proliferator-activated receptor (PPAR). RXR
has a ligand but activation of RXR is likely not involved in T3 responsiveness (Chandra
et al, 2008; Lefebvre et al, 2010).
Positive TRE
The genes which are stimulated by thyroid hormones contain a positive thyroid
response element (pTRE). Mostly pTRE are located upstream from the transcription start
site but they can also be present in the intron or 3' flanking region A typical pTRE
consists of a core consensus hexanucleotide half site (A/G) GGT(C/G)A. The half site
binding motif can be further arranged as palindromes (TRE PAL), direct repeats (DR)
and inverted palindrome (TRE IP) separated by six of nucleotides. The most common
motif is a direct repeat separated by 4 nucleotides (DR4) (Bassett et al, 2003). The
common TREs are shown in Table 1-2.
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Table 1-1.

Examples of genes regulated by T3

Induced genes
Pyruvate dehydrogenase kinase 4
Phosphoenolpyruvate carboxykinase
Carnitine palmitoyltransferase 1A
Malic enzyme
Growth hormone
Mylein basic protein
Fatty acid synthetase
Myosin heavy chain

Table 1-2.

Inhibited genes
Thyroid stimulating gene α
Thyroid stimulating gene β
Prohormone convertase
Necdin
Sterol element binding protein
Superdioxide mutase
Type II deiodinase
Epidermal growth factor receptor

Consensus positive thyroid response elements

Type of TRE
Consensus half site
Direct repeat 4(DR-4)
Inverted palindrome
Palindrome

Nucleotide sequence
(A/G)GGT(C/G)A
AGGTCANNNNAGGTCA
TGACCTNNNNNNAGGTCA
AGGTCATGACCT
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Mechanism of Gene Activation by T3
Thyroid hormone induces the expression of a number of genes involved in
metabolism. The molecular mechanism of gene up regulation by T3 is better understood
than gene repression For positively regulated genes, TRs bind primarily as heterodimers
with RXR. The unliganded TR in a positive TRE is associated with corepressors like
SMRT, NCoR1 and HDACs leading to basal gene repression. Upon T3 binding, the helix
12 of TR undergoes conformational changes and the corepressors dissociate from the TR.
The repressor complex is replaced by coactivators, such as the steroid receptor SRC-1
and the CREB-binding protein (CBP) and p300. These coactivators CBP/p300 possess
intrinsic histone acetylase activity, which neutralizes the positive charge of lysine
residues of the histones, thereby loosening the wrapping of negatively charged DNA
against the histones. This leads to formation of open chromatin structure allowing
transcription factor and basal transcriptional machinery to accesses the gene promoter
causing gene activation (Grimaldi et al, 2013; Harvey & Williams, 2002). A model of
gene activation by T3 is shown in Figure 1-5.
Mechanism of Gene Inhibition by T3
Although one activity of liganded TR is to stimulate transcription, an important
regulatory role of T3 involves gene repression (Feng et al, 2000; Flores-Morales et al,
2002). Examples of genes inhibited by T3 include TSHα, TSHβ, necdin, prolactin, and
others. TSHα and TSHβ are crucial targets for negative feedback by T3 in pituitary. T3
suppresses many genes in liver (Weitzel et al, 2001).Unlike transcriptional stimulation,
the mechanisms by which T3 represses gene expression are poorly understood. In contrast
to positively regulated genes, many of the negatively regulated genes are stimulated by
unliganded TR and repressed by liganded TR. Different theories have been proposed to
explain the T3 mediated gene inhibition (Santos et al, 2011; Weitzel, 2008). Outlined
below are some of the proposed possible models by which liganded TR inhibits gene
transcription.
Direct DNA-Binding Model
TR binds directly to negative thyroid response elements (nTRE). This model
hypothesizes that the negatively regulated genes contain a negative thyroid response
element known as a nTRE. Binding of TR to this nTRE is responsible for gene repression
by T3.
Repression through negative TREs is considered to be one of the major
mechanisms of gene repression by TR (Duran-Sandoval et al). Some of the reported
nTREs are summarized in Table 1-3. The nucleotides critical for T3 responsiveness are
underlined. According to this mechanism, TR via its DNA binding domain binds directly
to nTRE and causes transcriptional repression in a T3 dependent manner. Negative TREs,
have been identified in the promoters of genes like TSHα and TSHβ. In contrast to
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Figure 1-5.

Classical model of gene activation by thyroid hormone

Mechanism of classical gene regulation by TR involves transcriptional repression via
recruitment of corepressors by unliganded TR. Liganded TR mediated activation involves
recruitment of coactivator complexes with HAT activity.
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Table 1-3.

Examples of negative thyroid response elements

Genes
Thyroid stimulating gene β
E2F
Necdin
Superoxide dismutase
CD44
Epidermal growth factor
Preprothyrotropin releasing hormone
Sterol regulatory element binding protein
Prohormone convertase 1
Prohormone convertase 2
β amyloid precursor protein
Sodium potassium ATPase α3

Negative thyroid response element
CGCCAGTGCAAAGTAA (Z box)
TCCGGACAAAGCCTGCGC (Z box)
TGTCGGAACAAAGTAAGG (Z box)
GCGAGGCGATTGGTTTGGGGCA
CCTCTCTTTGGGTGTGTT
GCCCGAGTCCCCGCCTCGCC
CCCGCTGACCTCACA
GCCTGACAGGTGAAATCGGC
TCCACTCA GCCTGGAGACCGA
AAGAGAGGCCATGTGTGTCG
GGGCAGAGCAAGGACG
CTGATTGGCCAAGAGCCCGCCTC
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positive TREs, the sequence requirements of negative TREs (nTRE) are poorly defined.
Generally, the nTREs have been identified close to the transcription start site and are
called Z boxes (CAAAG). nTREs loosely resembling to TRE-like half sites have been
reported. However, the binding of thyroid receptor to these nTREs is very weak
compared to DR4. Since the nTRE and pTRE differ considerably from each other,
questions were raised as to whether the TR binds directly to these elements. The concept
of a nTRE was strengthened by the studies of Sibuwasa et al where they found that a TRβ
defective in DNA binding was not able to suppress the expression of TSH gene both in
vitro and in vivo. These studies suggested that TR does binds directly to nTRE. However
the question of how the nTRE leads to gene repression rather than activation has not been
addressed. Below are a few mechanisms by which the nTRE could inhibit the gene
expression.
Interference Model
In this case, the nTRE functions via an interference mechanism (Figure 1-6). For
example, the nTRE in TSHβ gene lies near the transcription start site and thereby
interferes with formation of transcription initiation complex. Another possibility is that
the nTRE might overlap with the binding sites of other transcription factors. Binding of
T3 to the liganded TR prevents the binding of the transcription factor to its promoter
element leading to gene suppression. Examples include the β amyloid precursor protein
in which the nTRE overlaps with Sp1 binding site. Binding of TRβ precludes binding of
Sp1 thereby inhibiting Sp1 mediated induction. Likewise in epidermal growth factor
receptor gene promoter repression results from inference with Sp1 (Xu et al, 1993).
Similarly for CTCF-binding factors, nTRE and CRE overlap and mutation of CRE
eliminates the T3 effect.
Role Reversal Model
According to this mechanism the function of the coregulator proteins is reversed
(Figure 1-7). In a nTRE, coactivators promote repression while the corepressors lead to
gene activation. This mechanism has been proposed for a few negatively regulated genes.
It was reported that SMRT activated the TSHα via the nTRE (Berghagen et al, 2002).
Similarly for TRH gene, corepressors were found to cause the basal activation rather than
inhibition. Likewise, a TR mutant, defective in corepressor binding surface, was unable
to activate a nTRE in SOD gene promoter (Santos et al, 2006). Similarly, in SRC-1
knockout mice, deletion of SRC-1 affected the T3 mediated induction of positively
regulated genes, but surprisingly the T3 inhibition of TSHβ gene was also attenuated.
This suggests that for some negatively regulated genes coactivators might acts as
corepressors. Both promoter and cell environment are responsible for this role reversal.
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Figure 1-6.

Interference model of gene repression

Nuclear receptor interferes with the activation of other transcription factors. For example
TR prevents the binding of Sp1 to the β amyloid precursor gene.

Figure 1-7.

Coregulator role reversal model

The functions of regulatory proteins are reversed. Corepressor SMRT activates the TSHα
via the nTRE rather than inhibiting it.
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Inverse Recruitment Model
This model proposes that in some nTRE there is inverse recruitment of
coregulator proteins. Unlike the pTRE, the unliganded TR on the nTRE might be
associated with coactivator leading to gene activation while liganded TR recruits
corepressors causing gene inhibition.
This hypothesis is supported by a recent study (You et al, 2010) where mice were
made defective in the interaction of NCoR1 with HDAC3 by creating a mutation in the
deacetylase domain of NCoR1. In these mice, positively regulated T3 responsive genes
which are inhibited by unliganded TR were activated, while negatively T3 regulated
genes like TSHα and deiodinase 2 were modestly induced by T3. A model of inverse
recruitment is shown in Figure 1-8. This suggests that on negatively regulated genes like
TSHα and deiodinase 2 liganded TR might be associated with NCoR1. The exact
mechanism responsible for the switching of the coregulator proteins is not known. One
possible explanation for this inverse recruitment is DNA sequence (TRE) acts as
allosteric modulator for TR. Binding of TR can cause conformational changes in the TR
receptor such that liganded TR has affinity for corepressors rather than coactivators.
Recruitment of Ligand-Dependent Corepressors
Recruitment of coactivator by liganded nuclear receptors cannot fully account for
the actions of the nuclear receptors. This model proposes that ligand dependent
corepressors might be involved in negative gene regulation by nuclear receptors or some
coregulators might function as coactivator or corepressors in a gene dependent manner
(Figure 1-9). Examples of agonist dependent corepressors include receptor interacting
protein 140 (RIP140). RIP140 was initially identified as coactivator recruited to liganded
NRs including estrogen receptor alpha (ERα), TRα/β, androgen receptor (AR), vitamin D
receptor (VDR), PPARα and Liver x receptor α (LXRα) (Augereau et al, 2006). Later it
was found that RIP140 acts as a corepressor by competing for binding of coactivator to
liganded nuclear receptors. Furthermore, RIP140 recruits HDAC1 and 3 in case of
RAR/RXR heterodimer. Ligand dependent corepressor (LCoR) is another agonist bound
corepressors. It was first found to bind with the ERα receptor and later studies showed
that it interacted with other nuclear receptors. LCoR interacts with HADC3 and HDAC6.
Other examples of agonist bound corepressors include preferentially expressed antigen in
melanoma (PRAME), repressor of estrogen activity (REA) etc.
Transrepression
This mechanism involves the protein- protein interaction of nuclear receptors with
other transcription factors. In this case, nuclear receptors do not bind the gene promoter
directly, but instead interfere with the function of transcription factors through proteinprotein interaction (Figure 1-10) (Pascual & Glass, 2006). In addition to binding to T3
response element, the DBD of TR can interact with other transcription factors. Nuclear
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Figure 1-8.

Inverse recruitment of corepressors to ligand bound thyroid receptor

In this mechanism corepressors are associated with ligand bound TR. NCoR1 has been
found to be associated with ligand bound TR in nTRE of TSHα gene.

Figure 1-9.

Repression by recruitment of ligand dependent corepressors

Ligand dependent co repressors (LCoR1) are recruited to TR in response to T3 binding
leading to gene silencing.
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Figure 1-10. Transcriptional repression by transrepression mechanism
Ligand bound TR interferes with the binding of GATA-4 and prevents GATA-2 mediated
transcription. Similarly, ligand bound GR interacts and prevents AP-1 mediated gene
activation.
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receptors have been shown to inhibit the inflammatory genes via direct interaction of
NRs with NF-KB and AP-1. For example the DBD of GR interacts with NF-KB and AP1(Caldenhoven et al, 1995). Similarly PPARα interferes with the DNA binding of AP-1
and NF-KB in IL-6 mediated induction in vascular smooth muscle cells (Delerive et al,
1999).
Regarding transrepression by TR, with some of the genes repressed by T3, the
DBD for TR is not required. T3 inhibits hepatic angiopoietin like-3 (ANGPTL3) gene
expression via interactions of TRβ with HNF4 bound to the ANGPTL3 proximal
promoter (Fugier et al, 2006). Similarly another study on TSHβ suggests that TR via its
DBD interacts with transcription factor GATA-2, and liganded TR prevents the binding
of GATA to its response element. This model is very well established with respect to
glucocorticoid receptors (GR). Glucocorticoids are known to inhibit the expression of
various in inflammatory genes by tethering of GR to the NF-KB and AP-1 proteins.
Squelching or Sequestering Model
According to this model, the soluble non DNA bound TR in the nucleus
sequesters the cofactors from the DNA bound TR-cofactor complexes. In the presence of
T3, soluble TR competes for coactivator thereby limiting the amount of coactivator to
DNA bound TR leading to gene repression. The idea of this hypothesis is supported by a
study by Gill et al where they found that overexpression of GAL4 inhibited the
expression of genes not containing the GAL4 binding sites. It was proposed that
transcriptional activator GAL4 was squelching the transcriptional machinery (TATA
binding proteins and RNA polymerase II). This model had been proposed to the
negatively regulated genes which do not require the DBD of TR for their inhibition (Gill
& Ptashne, 1988).
Thyroid Hormone Actions
T3 modulates lipid metabolism, plasma lipids and cardiovascular function. The
physiological actions of T3 are mediated through TRα and TRβ (Forrest & Vennstrom,
2000; Wu & Koenig, 2000; Zabrocka & Klimek, 2004). The important functions of
thyroid hormone are summarized below:
Effect of T3 in Liver
Liver plays a critical role metabolism and about 5% of genes in liver are regulated
by T3. Lipid and glucose metabolism are the two of the major physiological processes
modulated by T3. T3 regulates every aspect of carbohydrate metabolism in the liver. It
induces gluconeogenesis by increasing the expression of phosphoenolpyruvate
carboxykinase (PEPCK) and glucose 6 –phosphatase (G6-P) genes.T3 reduces lipogenesis
by inhibiting the expression of lipogenic gene sterol regulatory element binding protein
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(SREBP-1c). T3 regulates cholesterol metabolism. It induces the expression of the LDLreceptor (LDL-R), increasing the hepatic uptake of LDL from blood. Expression of
CYP7A1, the enzyme involved bile acid synthesis from cholesterol, is induced by T3. The
net result of elevated T3 is increased cholesterol clearance (Pramfalk et al, 2011; Weiss et
al, 1998; Yen, 2001).
Effect of T3 in Heart
Thyroid hormone increases heart rate, cardiac contractility and cardiac output.
The actions of T3 in heart are mainly mediated by the TRα isoform. T3 induces
expression of the β1-adrenergic receptor via TRα and thereby elevates β-adrenergic
responsiveness. Additionally, T3 increases the expression of genes critical for cardiac
function. By inducing the expression of myosin heavy chain and sarcoplasmic reticulum
Ca2+- ATPase, T3 enhances cardiac output and decreases relaxation time (Danzi & Klein,
2002; Silva & Bianco, 2008).
Effect of T3 in Adipose Tissue
Thyroid hormone regulates the function of both white adipose tissue (WAT) and
brown adipose tissue (BAT). In WAT, it induces differentiation from pre-adipocytes to
adipocytes. T3 promotes both lipogenesis and lipolysis. It induces lipolysis by increasing
sensitivity of adipose tissue to adrenergic stimulation and increasing the activity of
hormone sensitive lipase. In BAT, T3 promotes thermogenesis by enhancing the response
of norepinephrine signaling pathway and inducing the expression of uncoupling protein 1
gene (Silva, 1995; Silva, 2011).
Effect of T3 in Brain
T3 is essential for normal brain development. Hypothyroidism in neonatal period
leads to mental retardation and neurological defects. Hypothyroidism in neonatal rats
leads to decreased axonal growth and dendritic arborization in cerebellum, cerebral
cortex and hippocampus (Pilhatsch et al, 2010; Wallis et al, 2010).
TRβ Agonists
Therapeutic potential of thyroid hormone as a lipid-lowering and anti-obesity
agent remains largely hampered by dose-limiting cardiac effects, muscle wasting and
osteoporosis mediated by the TRα isoform. Considerable effort has been made to develop
TRβ selective modulators due to their preferential effect on liver metabolism (Baxter &
Webb, 2009). Examples of some of the known TRβ agonists are given below:
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GC-1
GC-1 named as sobetirome, is a selective thyromimetic with a 10-fold preferential
affinity for TRβ1 over TRα1. It accumulates preferentially in liver as compared to other
tissues. In rodents and primates, it lowered cholesterol levels and reduced hyperlipidemia.
GC-1 increased hepatic fatty acid oxidation in mitochondria and peroxisomes but to a
lesser extent than T3. Importantly heart rate and cardiac performance were not altered
(Baxter et al, 2004; Johansson et al, 2005; Perra et al, 2008).
MB07811
MB07811 is a TRβ selective liver prodrug. In the liver, it is metabolized into an
active metabolite MB07344. In a study by Cable et al, MB07811 reduced hepatic
steatosis and hepatic triglycerides in both rats and mice. It induced CPT1a and PGC-1α
while inhibiting SREBP-1c expression (Cable et al, 2009; Erion et al, 2007).
KB-141
KB-141 is another TRβ agonist which is more selective for stimulating metabolic
rate and is 30-fold more selective for cholesterol lowering than for positive chronotropic
effects. In primates, it caused significant cholesterol reduction and weight loss and
(Grover et al, 2005). In ob/ob mice, KB141 was found to reduce serum triglycerides and
non-esterified free fatty acid (Amorim et al, 2009).
GC-24
GC-24 has demonstrated ability to reduce body fat accumulation and to prevent
liver steatosis in rats with diet-induced obesity and increasing energy expenditure.
However, GC-24 reduced only marginally total cholesterol levels and did not have any
effect on free fatty acids or IL-6 levels (Amorim et al, 2009).
KB-2115
KB-2115 is the only TRβ selective compound that has been used in human trials
(Tancevski et al, 2011). In 2 week clinical trials, KB2115 lowered the LDL cholesterol
by 40%. In another clinical trial, the patients were already on statin therapy. Following
100µg or 200µg dose of KB2115 for 12 weeks there was a 30% decrease in the LDL
cholesterol and a significant reduction in triglycerides. There was no change in heart rate
and muscle strength (Ladenson et al, 2010).
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Phospholipase A2
Phospholipases A2 are a family of esterase enzymes which hydrolyze the second
carbon of membrane phospholipids to release non-esterified free fatty acid and
lysophospholipids. These products generated could either serve as secondary messengers
or be metabolized to generate bioactive molecules. For example, the free fatty acid
(arachidonic acid) is a precursor for inflammatory mediators such as prostaglandins.
Similarly the lysophospholipids (lysophosphatidylcholine or lysophosphatidic acid) may
be converted to lipid mediators like platelet activating factor. In mammals, more than 30
enzymes having phospholipase activity have been identified (Murakami & Lambeau,
2013). The reaction catalyzed by of phospholipase A2 is shown in Figure 1-11.
Classification of Phospholipases
Based on their Ca2+ ion requirement and cellular localization, PLA2 enzymes
have been classified into four groups: cytosolic phospholipase A2, secretory
phospholipase A2, calcium independent phospholipase A2 and lipoprotein associated
phospholipase A2 (Balsinde et al, 2002; Dennis et al, 2011; Jaross et al, 2002; Kudo &
Murakami, 2002).
Cytosolic phospholipase A2 (cPLA2s). cPLA2 belong to the category of
intracellular PLA2. These are located in the cytosol and migrate to nuclear membranes in
response to inflammatory stimuli. They usually have a molecular mass greater than 60
kDa and require Ca2+ ion for their enzymatic activity. This family has a conserved Nterminal C2 domain for calcium dependent association with cellular membrane. The
cPLA2s have a preference for the phospholipids containing arachidonic acid. This
category includes 6 isoforms which includes cPLA2 IV A (cPLA2α), cPLA2 IVB
(cPLA2β), cPLA2 IVC (cPLA2γ) cPLA2 IVD (cPLA2ζ), cPLA2 IVE and cPLA2 IVF
(Burke & Dennis, 2009; Lucas & Dennis, 2004).
Secretory phospholipases (sPLA2s). sPLA2 are stored in cytoplasmic granules
and are secreted into the extracellular environment in response to stimuli. These are low
molecular weight phospholipases with a size of 14-18 kDa. These enzymes require mM
concentrations of calcium for their enzymatic activity. They contain a highly conserved
Ca2+ binding loop (CXCGXGG) and a catalytic (DXCCXXHD) domain. This group is
cationic in nature and have 6-8 disulphide bonds which impart high degree of stability to
these enzymes. Currently 11 sPLA2s have been identified in humans. This class includes
PLA2gIB, PLA2gIIA, PLA2g IIC, PLA2gIID, PLA2gIIE, PLA2gIIF, PLA2gIII,
PLA2gV, and PLA2gX (Dennis et al, 2011).
Calcium-independent phospholipase A2 (iPLA2s). iPLA2 also called patatin
like phospholipases, are high molecular weight cytosolic phospholipases which do not
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Figure 1-11. Enzymatic reaction catalyzed by PLA2
Phospholipases hydrolyzes the membrane phospholipids to release free fatty acid and
lysophospholipids. Based on the cellular localization, phospholipases has been divided
into intracellular cytosolic PLA2, calcium independent PLA2 and extracellular secreted
PLA2.
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require Ca2+ ion for their enzymatic activity. Group VI iPLA2 is an 85-88kDa enzyme.
This class includes phospholipase group PLA2gVIA, PLA2gVIB, PLA2gVIC,
PLA2GVID, PLA2GVIE, and PLA2GVIF. These are also known as lipase type enzymes
since many of them act on neutral lipids like triglycerides rather than acting on
phospholipases (Kudo & Murakami, 2002).
Lipoprotein-associated phospholipase A2 (Lp-PLA2). It is a 45kDa sPLA2
secreted by the macrophages, T lymphocytes and mast cells. This enzyme has plateletactivating factor acetyl hydrolase activity along with phospholipase activity. Lp-PLA2 is
usually associated with oxidized plasma lipoproteins (Murakami, 2004).
General Functions of Secretory Phospholipases
Secretory phospholipases have a wide variety of functions. sPLA2s can act on the
cellular membranes in an autocrine and paracrine manner. Besides generating arachidonic
acid, they also generate other saturated, mono and polyunsaturated fatty acids. Various
non-cellular phospholipids such as microbial membrane, dietary phospholipids,
lipoproteins and pulmonary surfactants are their other targets. sPLA2 stimulates
inflammation independent of its catalytic activity. sPLA2 binds to the M-type PLA2R
receptors present on the surface of mast cells, neutrophils, macrophages and induce the
production of cytokines by these cells. However, the binding of sPLA2 to PLA2R1
internalizes sPLA2 into phagolysosomes leading to its degradation (Mallat et al, 2007).
The physiological actions of sPLA2s are shown in Figure 1-12.
sPLA2g2a
PLA2g2a is a secretory PLA2 which is also known as non-pancreatic or
inflammatory PLA2. It was first purified from the platelet and the synovial fluids of
patients suffering from arthritis (Pruzanski & Vadas, 1988).
Enzymatic Properties
PLA2g2a is highly cationic in nature due to the presence of histidine, arginine and
lysine residues. It has high affinity for anionic phospholipids such as phosphatidylserine
and phosphatidyl ethanolamine and phosphatidylglycerol as compared to neutral
phosphophatidylcholine (Dennis et al, 2011).
Expression
High levels of this enzyme have been found in plasma and other biological fluids
of patients suffering from various inflammatory diseases. Many cell types including
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Figure 1-12. General functions of secretory phospholipases
Based on their enzymatic properties, sPLA2 can hydrolyze membrane phospholipids, and various other non-cellular targets
like dietary phospholipids, microbial membrane and micro vesicles. By binding to M-type receptor via their non-enzymatic
properties they could promote cell proliferation, and inflammation.
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hepatocytes, vascular smooth muscle cells and endothelial cells secrete PLA2g2a. Liver
is one of the major contributors of sPLA2 in human plasma along with vascular smooth
muscle cells. Liver biopsies of patients with acute pancreatitis revealed increased
PLA2g2a expression in liver and elevated serum PLA2g2a levels.
Regulation of PLA2g2a
Expression of PLA2g2a is induced by various stimuli including interleukin 1 (IL1), interlukin-6 (IL-6), tumor necrosis factor α (TNFα), lipopolysaccharides (LPS) and
cyclic AMP (Massaad et al, 2000). IL-1β induces the transcription of PLA2g2a through
NF-KB and peroxisome- proliferator activated receptors while cAMP acts via CCAAT
enhancer binding protein (CEBPβ) to stimulate PLA2g2a (Antonio et al, 2002; Couturier
et al, 2000; Fan et al, 1997).
Functions of PLA2g2a
Role of PLA2g2a in inflammation. The fact that PLA2g2a is highly abundant in
the biological fluids of patients suffering from inflammatory diseases like arthritis, sepsis
and myocardial infarctions led to the hypothesis that PLA2g2a promotes inflammation. In
a study (Boilard et al, 2010), PLA2g2a knockout BALB/c mice had attenuated joint
inflammation as compared to wild type BALB/c mice.
Role of PLA2g2a in atherosclerosis. PLA2g2a has proatherogenic properties
and elevated levels of PLA2g2a are a biomarker for cardiovascular diseases (Kugiyama
et al, 1999). The first evidence for the role of PLA2g2a in atherosclerosis came from a
study with PLA2g2a Tg mice. THE C57BL/6 mice do not express PLA2g2a due to frame
shift mutation in exon 3. The human PLA2g2a was introduced into C57BL/6 mice. These
PLA2g2a Tg mice when fed on a high cholesterol atherogenic diet showed increased
atherosclerotic lesions and reduced plasma HDL (Ivandic et al, 1999). Transplantation of
bone marrow from PLA2g2a Tg mice into LDL receptor deficient mice resulted in a
significant increase in atherosclerotic lesions. Overexpression of PLA2g2a in mouse
macrophages accelerated the development of arterial wall lesions and the movement of
cholesterol from LDL to foam cells (Ghesquiere et al, 2005; Webb et al,
2003).Varespladib an inhibitor of sPLA2 had been reported to prevent the development
of atherosclerosis in guinea pigs (Leite et al, 2009). In a study a high-fat diet model,
Varespladib (A-002) reduced aortic atherosclerosis by 50% and reduced plasma total
cholesterol levels. Oral dosing of A-002 for 16 weeks significantly reduced aortic
atherosclerosis in the ApoE-/- mice model. The reduction was associated with a
significant decrease in total cholesterol (Fraser et al, 2009).
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Role of PLA2g2a in metabolic syndrome. Transgenic mice were generated that
express the human PLA2g2a gene regulated by the human promoter. When these mice
were placed on a high cholesterol diet, there was elevated accumulation of cholesterol in
the liver suggesting that PLA2g2a impacts hepatic cholesterol uptake (Eckey et al, 2004).
Another study provided evidence of possible role of PLA2g2a in diet induced obesity and
metabolic dysfunction. In high fat diet induced obesity rat models the levels of PLA2g2a
were elevated 20 fold in white adipose tissue. Inhibition of PLA2g2a by the selective
PLA2g2a inhibitor KH064 protected rats against diet induced metabolic dysfunction and
adiposity. They proposed that PLA2g2a inhibition improved adipose tissue function via
stimulating lipolysis there by decreasing fat stores in adipose tissue. Genes involved in
lipid metabolism and energy expenditure like peroxisome- proliferator activator receptor,
adiponectin, hormone sensitive lipase were induced by KH064.
Role of PLA2g2a in bacterial infection. PLA2g2a can hydrolyze the bacterial
membrane phospholipids like phosphatidyl ethanolamine and phosphatidylglycerol
thereby providing antibacterial activity. Tg mice overexpressing PLA2g2a showed
decreased mortality against Gram negative bacterial infection (Laine et al, 1999; Laine et
al, 2000).
sPLA2g1b
sPLA2g1b often named as pancreatic phospholipase A2 is mainly expressed in
pancreatic acinar cells. It is found within zymogen granules of the acinar cells. It will
promote lysophospholipid absorption. PLA2g1b KO mice when fed on high
fat/carbohydrate diet showed resistance to the effects of diet-induced obesity, diabetes
and hyperlipidemia. PLA2g1b gene lies in a locus for obesity susceptibility in humans
(Wilson et al, 2006). PLA2g1b KO mice showed increased glucose tolerance and
improved insulin sensitivity as compared to wild type mice (Hollie & Hui, 2011; Labonte
et al, 2010). The PLA2g1b inhibitor methyl indoxam was able to reduce diet induced
obesity, hypercholesterolemia and hyperglycemia in the rats fed on high fat high
carbohydrate diet.
sPLA2g3
Unlike other sPLA2s, PLA2g3 is large protein of 55 kDa. It is highly expressed in
epididymal epithelium and dorsal root ganglionic neurons. PLA2g3 KO mice show
reduced sperm motility and reduced ability to fertilize intact eggs suggesting the role of
PLA2g3 in sperm maturation (Sato et al, 2010). In addition, PLA2g3 can hydrolyze HDL
and LDL. PLA2g3-modified LDL promoted the formation of lipid droplet-rich foam cells
from macrophages. Furthermore, atherosclerosis was exacerbated in PLA2g3 Tg × apoE
KO mice fed a high cholesterol diet (Sato et al, 2008). PLA2g3Tg mice also showed
chronic inflammation and dermatitis.
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sPLA2g5
PLA2g5 is highly expressed in macrophages, bronchial epithelium, and
myocardium. In the lung, PLA2g5 expression is elevated in mice models of asthma or
acute respiratory distress syndrome (ARDS) mice models (Munoz et al, 2007; Munoz et
al, 2009). PLA2g5 transgenic mice showed reduced lung surfactant phospholipids like
diapalmitoyl phosphatidylcholine and phosphatidylglyecerol leading to respiratory failure
and neonatal death (Ohtsuki et al, 2006). PLA2g5 is expressed in human atherosclerotic
lesions and has been proposed to play an important role in promoting atherosclerosis
(Bostrom et al, 2007). It was reported that PLA2g5 hydrolyzed LDL were more
susceptible to form macrophage foam cell formation.
sPLA2g10
PLA2g10 is expressed in neutrophils, intima of human atherosclerotic lesion and
in alveolar macrophages and airway epithelial cells. Similar to PLA2g1b, PLA2g10 is
produced as a zymogen (Cupillard et al, 1997). It will modify LDL and promote foam
cell formation and atherosclerosis. PLA2g10 knockout mice have reduced allergen
induced asthma (Henderson et al, 2007).
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CHAPTER 2.

RESEARCH OBJECTIVE
Hypothesis-1

T3 status modulates sPLA2 expression by inhibiting the expression of PLA2g2a
and other sPLA2 isoforms in liver.
Hypothesis-2
The second hypothesis was that T3 inhibits the expression of PLA2g2a via a
negative thyroid response element and that nuclear corepressors are recruited to nTRE in
a T3 dependent manner.
Aim 1: To Characterize the Regulation of PLA2g2a by Thyroid Hormone in Liver
Clinical studies have correlated hypothyroidism with low grade inflammation,
elevated risk of hepatic steatosis and atherosclerosis. (Ichiki, 2010; Kvetny et al, 2004).
PLA2g2a is involved in inflammation, atherosclerosis and hyperlipidemia. The linkage of
hypothyroidism and inflammation led us to investigate the modulation of PLA2g2a
expression by T3. Since the liver is one of the major contributors to the total pool of
PLA2g2a in plasma, I propose to characterize the regulation of PLA2g2a and other
sPLA2s by thyroid hormone in liver.
Specific aim 1-1: To investigate the effect of thyroid hormone status on the
regulation of PLA2g2a and other sPLA2 in liver in vitro and in vivo. I will study the
effect of T3 on PLA2g2a expression in rat hepatocytes and human hepatoma cells. I will
investigate whether the thyroid status regulates the endogenous sPLA2 gene expression
in vivo in rats. Rats will be made hypothyroid by providing an iodine free diet
supplemented with propylthiouracil (PTU) for five weeks. T3 will be administered to
make them hyperthyroid. The effect of thyroid status will be then measured on the
abundance of PLA2g2a and other sPLA2 isoforms.
Specific aim 1-2: To study the effect of thyroid hormone on cytokines
mediated induction of PLA2g2a gene. Since the PLA2g2a is an inflammatory enzyme,
expression of PLA2g2a is induced by various cytokines like interleukin 1(IL-1),
interluekin-6 (IL-6), tumor necrosis factor α (TNFα), and lipopolysaccharides (LPS). I
will investigate whether T3 can block the cytokine mediated induction of PLA2g2a. Rat
hepatocytes and HepG2 cells will be treated with cytokines TNFα and IL-6, respectively.
The effect of T3 will be then studied on the cytokine mediated induction of PLA2g2a.
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Aim 2: To Identify the Mechanism of Negative Gene Regulation of PLA2g2a
by T3
The mechanisms by which T3 inhibits hepatic gene expression are not understood.
I will address this question by using PLA2g2a as my model gene. I hypothesize that T3
reduces PLA2g2a expression via a nTRE and that the liganded TRβ recruits corepressors
to the PLA2g2a gene to inhibit the expression of PLA2g2a gene.
Specific aim 2-1: To identify the negative thyroid response element in
PLA2g2a promoter. A consensus motif for the nTRE has not been defined. The nTREs
do not resemble a classical positive TRE (pTRE) consisting of an AGGTCA motif
separated by four nucleotides (DR4). To identify the T3 responsive element, I will clone
the rat PLA2g2a promoter and fuse it to the luciferase (luc) reporter. To localize the
nTRE response element I will create 5' serial deletions of the PLA2g2a promoter. The
binding of TRβ will be tested. Site directed mutagenesis of PLA2g2a-luc will be
conducted to identify T3 inhibitory elements functionally. I will ligate the nTRE in front
of TK-luciferase to determine if PLA2g2a promoter context is critical for the inhibition
by T3. This experiment will determine if the sequence of the nTRE is sufficient to impart
inhibition by T3 or if other factors bound to the PLA2g2a promoter are needed for the
repression of gene expression.
Specific aim 2-2: Identification of the coregulatory proteins involved in
PLA2g2a repression by T3. I hypothesize that on a nTRE TRβ recruits corepressors to
inhibit PLA2g2a transcription. Several approaches will be used to investigate whether
corepressors are involved in the T3 mediated repression or not. I will knockdown
NCoR1and SMRT using siRNA. I will test whether the T3 inhibition of PLA2g2a is lost
by corepressor knockdown. ChIP assays will be conducted to assess the T3 dependent
recruitment of NCoR1 and SMRT to the PLA2g2a gene. I will make TRβ mutants with
altered amino acids in helices 1 and 3 which are known to be defective in corepressors
binding. These mutations will diminish the interaction of TRβ with NCoR1 and SMRT
(Collingwood et al, 1998; Marimuthu et al, 2002a). I will identify the other genes which
require the nuclear corepressors for T3 mediated inhibition of gene expression.
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CHAPTER 3.

REGULATION OF SECRETORY PHOSPHOLIAPSES BY
THYROID HORMONE*
Introduction

Several studies have correlated hypothyroidism with elevated risk of
atherosclerosis, hepatic steatosis and components of the metabolic syndrome including
hyperlipidemia and obesity (Baxter & Webb, 2009). Chronic low-grade inflammation is
associated with obesity and hypothyroidism (Garces et al, 2010; Kvetny et al, 2004). The
Secretory phospholipase PLA2g2a enhance the progression of several chronic
inflammatory diseases including arthritis and atherosclerosis (Murakami et al, 2011).
PLA2g2a promotes conversion of LDL to the more atherogenic oxidized LDL (Lambeau
& Gelb, 2008). Most studies on PLA2g2a expression have been conducted in vascular
cells and macrophages with respect to atherosclerosis and arthritis (Murakami et al,
2010). However, the liver is one of the major contributors to the total pool of
extracellular sPLA2 (Exeter et al, 2012; Grass et al, 1996) and hepatocytes secrete
PLA2g2a in response to cytokines (Adamson et al, 1994; Crowl et al, 1991; Nevalainen
et al, 1996). Since PLA2g2a expression is elevated in various inflammatory states and
hepatocytes actively secrete PLA2g2a, we investigated the regulation of PLA2g2a in
liver. The potential linkage of hypothyroidism with inflammation led us to examine the
modulation of PLA2g2a expression by T3.
In this chapter, I characterized the regulation of PLA2g2a by T3 in liver. I found
that T3 decreases both the mRNA and protein abundance of PLA2g2a by 60% in primary
rat hepatocytes as well as in human hepatoma cell lines (HepG2). I found that the thyroid
status regulates endogenous PLA2g2a gene expression in rats and BALB/c mice.
Hyperthyroid rats had significantly lower levels of PLA2g2a mRNA and proteins as
compared to hypothyroid rats Likewise, other sPLA2 isoforms including PLA2g1b,
PLA2g3 and PLA2g5 were inhibited in hyperthyroid rats. Similarly BALB/c
hyperthyroid mice had significantly lower levels of PLA2g2a as compared to
hypothyroid mice. Moreover, T3 also reversed the cytokines mediated induction of
PLA2g2a by 50%. Both in primary rat hepatocytes and HepG2 cells TNF and IL-6
mediated induction of PLA2g2a was inhibited by T3. I discovered that PLA2g2a is
induced by high fat diet both in primary rat hepatocytes and in vivo in BALB/c mice.
In conclusion, found that T3 inhibits the expression of PLA2g2a and other sPLA2
isoforms in primary rat hepatocytes, human HepG2 cell lines as well as in vivo in both
rats and mice livers. My data suggest that the thyroid status may modulate aspects of the
inflammatory response.
* Adapted with permission. Sharma P, Thakran S, Deng X, Elam MB, Park EA. (2013).
Nuclear Corepressors Mediate the Repression of Phospholipase A2 Group IIa Gene
Transcription by Thyroid Hormone J. Biol Chem, 2013 June 7; 288(23):16321-33.
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Material and Methods
Primary Rat Hepatocyte Cell Culture and Treatment
Rat hepatocytes were prepared by collagenase perfusion as described previously
(Zhang et al, 2004). Hepatocytes (3 × 106 in 60mm dishes) were maintained for 12 h in
RPMI 1640 media and 10% fetal bovine serum. The cells were then washed two times
with 1XPBS. RPMI 1640 media without serum was then added to the cells. The cells
were treated with 100 nM T3 for 24 h. TNFα was added to the cells at a concentration of
25 ng/mL.
RNA Extraction
Growth media was aspirated from the plates and 1mL of RNA stat 60 was added
to each 60 mm plates. After 5 minutes of incubation at room temperature, cells were
scrapped and transferred to 1.5ml eppendorf tubes. 0.2 mL of chloroform was added to
the homogenate and the tube were shaken vigorously for 15 sec. Tubes were then stored
at RT for 10 min, followed by centrifugation at 12000g for 20 min at 4 °C .The aqueous
layer was transferred to fresh tubes and the RNA was precipitated by using 0.5 mL of
isopropanol and centrifuging at 12000 g for 20 min. The supernatant was removed and
the pellet was washed with 75% ethanol by centrifuging at 7500 rcf for 5 minutes. Pellets
were air dried and dissolved in nuclease free water. RNA was f purified with the Qiagen
RNeasy Mini Kit (74104) and quantified using a NanoDrop machine.
Animals and Treatments
Adult male Sprague Dawley rats and BALB/c mice were housed under controlled
conditions (22 °C, constant humidity, 12 h/12 h dark/light cycle) in the animal care
facility of the University of Tennessee Health Science Center. Hypothyroidism was
induced in both by feeding an iodine-free diet containing 0.15% propylthiouracil (Teklad
95125) for 5 weeks. The rats/mice were given intraperitoneal injection of T3 (0.33 mg/kg
and 0.11 mg/kg of body weight respectively) (Cook et al, 2001) after 24 hrs another bolus
of same dose of T3 was given. Rats / mice were sacrificed after 24 hrs and livers were
isolated for RNA and protein.For high fat diet experiments BALB/c mice were divided
into three groups 1) chow fed (Teklad Diet 06101), 2) high fat diet (HFD) (TD 95217), 3)
hypothyroid (PTU) (TD 120714). The energy content of the HFD was 45% fat and 40%
carbohydrate while the chow diet has 65% carbohydrate and 17% fat.C57BL/6
hPLA2gIIA+ mouse contained the human PLA2g2a gene under the regulation of its own
promoter. These mice were provided to us by Dr. Eric Boilard in Quebec Canada. To
induce hypothyroidism, PTU was added at 0.05% in the iodine free diet for 6 weeks.
Each group of mice has seven female mice. C57BL/6 hPLA2gIIA+ were made
hyperthyroid by giving them two intraperitoneal injection of T3 (0.11 mg/kg of body
weight) for two days. After 24 hrs of second injection mice were sacrificed blood and
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liver were collected.
ELISA
HepG2 cells were plated in 24 well plates at a density of 0.2×106 cells/well in
DMEM media supplemented with 5% fetal bovine serum (FBS) and 5% bovine serum
(BS) and 1% penicillin and streptomycin. The following day serum free DMEM was
added to the cells and cells were treated with desired treatments. After 24 hours cell
culture media was collected in eppendorf tubes and centrifuged at 1200 rpm to ensure
that the cell supernatant was free of cell debris. ELISA was performed for PLA2g2a
(human Type IIA) using EIA Kit from Cayman Chemicals (585000).
Western Blot
Western blot analysis was performed on whole cell extracts from rat hepatocytes
and rat liver (Attia et al, 2011). Cells/ rat liver were harvested in RIPA buffer (50 mM
Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM EDTA pH 8.0, 1% Triton, 1 mM benzamidine,
0.5 mM PMSF and protease inhibitor cocktail) by sonicating at medium setting for 30
seconds. The lysate were kept on ice for 30 minutes. Cell debris was removed by
centrifugation at 12,000 rpm for 20 min at 4°C. The supernatant was then transferred to
fresh tubes. An equal amount of protein was loaded on a 3-8% Tris-acetate acrylamide
gel and transferred to a 0.22-µm nitrocellulose membrane (Bio-Rad, Hercules, CA). The
membranes were immunoblotted with primary antibodies PLA2g2a (Abcam) and Actin
(A3853, Sigma) in Tris buffered saline with Tween 20 containing 5% nonfat dry milk
powder. Membranes were incubated with horseradish peroxidase-conjugated anti-rabbit
secondary antibody. Immunoreactive proteins were detected using Super signal West
femto chemiluminescent substrate (Thermo Scientific).
Statistical Analysis
The Student's one/two tailed t test or ANOVA was used to analyze the data. The
error bar indicates S.E.M. Significance is calculated relative control vs. T3 (* = p value <
0.05; ** = p value <0.01; *** = p value <0.001).
Real Time PCR
2.5 µg of RNA was reverse transcribed to cDNA using Superscript III
(Invitrogen). The resulting cDNA was diluted 1:5 in nuclease free water for real time
PCR reactions. The parameters for real time PCR were as follows: 95°C for 5 min, 40
cycles of 95°C for 15 s, 60°C for 30 s and 72°C for 10 s. The target genes were
normalized with the 18S gene. Quantification of the PCR products was carried out using
ΔΔCt method. List of the forward and reverse is provided in Table 3-1.
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Table 3-1.

List of primers for RT-PCR

Genes
Rat PLA2g2a F
Rat PLA2g2a R
Rat PLA2g1b (qiagen)
Rat PLA2g3 F
Rat PLA2g3 R
Rat PLA2g5 F
Rat PLA2g5 R
Rat 18 S F
Rat 18 S R
Rat FASN F
Rat FASN R
Rat SREBP-1c F
Rat SREBP-1c R
Rat PDK4 F
Rat PDK4 R
Rat CPT-1a F
Rat CPT-1a R
Hu PLA2g2a F
Hu PLA2g2a R
Hu PLA2g1b (qiagen)
Hu CPT1-a F
Hu CPT1-a R
Hu PEPCK F
Hu PEPCK R
Hu FASN F
Hu FASN R
Hu PDK4 F
Mice PLA2g2a F
Mice PLA2g2a R
Mice PEPCK
Mice CPT-1A
Mice PDK4

Primers
CATGGCCTTTGGCTCAATTCAGGT
ACAGTCATGAGTCACACAGCACCA
QT00179529
ACAGCCTTGAACTTCTGGTCCACT
GCTTTGAGCAGGTTGAAGCGTTG
AACTGTGTGGTCTTGAACCTCCGT
ACACACTCTCATGCAGCCTACCAT
CGGCTACCACATCCAAGGAA
TTTTCGTCACTACCTCCCCG
TGGAGAAGCCCAGGAACAACTCAT
ACCGAGTAATGCCGTTCAGTTCCT
CATGGATTGCACATTTGAAGAC
GCAGGAGAAGAGAAGCTCTCAG
GGATTACTGACCGCCTCTTTAGTT
GCATTCCGTGAATTGTCCATC
CGGTTCAAGAATGGCATCATC
TCACACCCACCACCACGAT
CATGGCCTTTGGCTCAATTCAGGT
AGGCTGGAAATCTGCTGGATGTCT
QT00000637
TGGCGTCTGAGAAGCATCAGCATA
ACACCACGTAAAGGCAGAAGAGGT
ATGTCAACTGGTTCCGGAAGGACA
TTTCAGGTTCAGGGCATCCTCCTT
AGGTTTGATGCCTCCTTCTTCGGA
TGGCTTCATAGGTGACTTCCAGCA
ACAGAGCCTGATGGATTTGGTGGA
AGCCTCGATCATGGCCTTT
GCCGAATCATTTCCCCAAA
QT00153013
QT00106820
QT00157248
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Results
Thyroid Hormone Inhibits PLA2g2a Expression in Primary Rat Hepatocytes
My first experiment characterized the regulation of PLA2g2a gene expression by
T3. Primary rat hepatocytes were treated with 100 nM T3 for 24 h. The next day cells
were harvested and the mRNA and protein abundance of PLA2g2a was measured. In
hepatocytes, there was a 48% decrease in the PLA2g2a mRNA levels (Figure 3-1A). The
PLA2g2a protein abundance was reduced nearly 70% by T3 (Figure 3-1B). To examine
whether T3 had similar effects in human hepatoma cells, HepG2 cells were treated with
T3. Both the levels of mRNA as well as secreted PLA2g2a protein in cells media as
measured by ELISA were decreased 50% (Figure 3-1C and 3-1D).These data suggests
that T3 inhibits the expression of PLA2g2a in human and primary hepatocytes.
T3 Has No Effect on the mRNA Stability of PLA2g2a
To rule out the possibility of nongenomic effects of T3, I conducted a time course
study for PLA2g2a mRNA abundance. No rapid T3 effect was observed and a significant
reduction in PLA2g2a mRNA levels was seen after 12 h (Figure 3-2A). These results
suggested that the T3 inhibits PLA2g2a via genomic actions. T3 could inhibit PLA2g2a
gene expression by decreasing its mRNA stability. To test this possibility I had treated
primary rat hepatocytes with T3, actinomycin and actinomycin D along with T3. I found
that the mRNA half-life of PLA2g2a is nearly 12 hours as shown in Figure 3-2B. The
rate of mRNA decay was identical for actinomycin D and actinomycin D with T3 treated
cells suggesting that T3 does not impact the mRNA stability (Figure 3-2B).
Thyroid Hormone Decreases the Cytokine Mediated Induction of PLA2g2a
Since PLA2g2a is an inflammatory enzyme and is induced by various cytokines, I
investigated whether T3 could block the cytokine mediated induction of PLA2g2a. I
treated rat hepatocytes and HepG2 cells with TNFα and IL-6, respectively. Addition of T3
decreased the TNFα induced expression of PLA2g2a mRNA from 7 to 2.5-fold
(Figure 3-3A). Similarly, T3 treatment reduced the IL-6 mediated induction of PLA2g2a
mRNA from 10 to 5-fold (Figure 3-3B) in HepG2 cells. The levels of secreted PLA2g2a
protein as measured by ELISA were decreased following T3 treatment (Figure 3-3C).
Effect of Thyroid Hormone Status on sPLA2 Expression in Rats
Next, I investigated whether the thyroid status regulated the endogenous sPLA2
gene expression in vivo. Rats were made hypothyroid by providing an iodine free diet
supplemented with propylthiouracil (PTU) for five weeks. T3 was administered twice
0.33 mg/kg body wt.) at 24 hrs intervals. T3 administration decreased the hepatic
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Figure 3-1.

Thyroid hormone inhibits the expression of PLA2g2a

A) Rat hepatocytes were treated with 100 nM thyroid hormone (T3) for 24 hrs. PLA2g2a
mRNA levels were measured by real time PCR. B) PLA2g2a protein levels were
measured by western analysis in rat hepatocytes. C) HepG2 cells were treated with 100
nM thyroid hormone (T3) for 24 hrs. PLA2g2a mRNA levels were measured by real time
PCR. D) PLA2g2a protein levels in HepG2 cells were measured by ELISA. Data are
expressed as the relative RNA or protein expression. All experiments were repeated 4 to
6 times. The data are expressed as the mean of the fold induction by T3 ± S.E.M of
mRNA abundance relative to untreated cells (** = p value <0.01; *** = p value <0.001).
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Figure 3-2.

T3 has no effect on the mRNA stability of PLA2g2a

A) Rat hepatocytes were treated with T3 for various times and PLA2g2a mRNA
abundance was measured. B) Hepatocytes were exposed to T3 or 5µg/ mL actinomycin D
or both. PLA2g2a mRNA levels in HepG2 cells were assessed the indicated time points.
Data are expressed as the relative RNA. All experiments were repeated 3-4 times. The
data are expressed as percent inhibition.
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Figure 3-3.

T3 inhibits the cytokine mediated induction of PLA2g2a

A) Rat hepatocytes were treated with 25 ng/mL TNFα or 100 nM T3 or both for 24 hrs.
PLA2g2a mRNA abundance was assessed. B) HepG2 cells were treated with 10 ng/mL
IL-6 or 100 nM T3 for 24 h. RNA abundance was determined. C) Media was collected
from HepG2 cells treated with IL-6 or T3 and the PLA2g2a levels were determined by
ELISA. All experiments were repeated 4 to 6 times. The data are expressed as the mean
of the fold induction ± S.E.M of mRNA abundance relative to untreated control cells (* =
p value < 0.05; ** = p value <0.01; *** = p value <0.001).
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expression of PLA2g2a mRNA. The isoform of sPLA2 were similarly inhibited by T3
suggesting that T3 modulates additional secretory PLA2 genes (Figure 3-4A and 3-4B).
Expression of the lipogenic gene SREBP-1c gene was decreased by T3 administration
(Figure 3-4C). Expression of other positively regulated genes was examined. Carnitine
palmitoyltransferase (CPT1a), phosphoenolpyruvate carboxykinase (PEPCK) and
pyruvate dehydrogenase kinase (PDK4) were all induced by T3 (Figure 3-4D-F). The
abundance of the PLA2g2a protein was decreased by T3 administration (Figure 3-4G).
T3 Inhibits PLA2g2a in BALB/c Mice
Since C57BL/6 have a “natural” knockout of PLA2g2a while BALB/c mice
express PLA2g2a. I tested whether the thyroid status similarly regulated PLA2g2a
expression in BALB/c mice. Mice were made hypothyroid by providing an iodine free
diet supplemented with 0.15% PTU for five weeks. T3 was administered twice at lower
dose (0.11 mg/Kg body wt.) at 24 hrs intervals for two consecutive days. Liver were than
harvested. RNA abundance of PLA2g2a (Figure 3-5A) and other positive control genes
were measured (Figure 3-5B-D). In hyperthyroid BALB/c mice PLA2g2a levels were
significantly decreased while the positive control genes like PDK4 and PEPCK were
induced.
Effect of Hypothyroidism and High Diet on the Expression of PLA2g2a
Since PLA2g2a was induced in the adipose tissue of rats which were on a high fat
diet (Iyer et al, 2012), I examined the ability of long chain fatty acids (LCFA) to directly
increase the expression of PLA2g2a. Addition of oleic acid (18:1) to hepatocytes elevated
PLA2g2a mRNA 3 fold, and this stimulation was inhibited by T3 (Figure 3-6A).
The effect of high fat diet was evaluated in BALB/c mice. These mice were
divided into three experimental groups: 1) chow fed (Teklad Diet 06101), 2) hypothyroid
(PTU) (TD 120714) 3) and high fat diet (HFD) (TD 95217). Hypothyroidism increases
the expression of PLA2g2a around 1.8 fold while PLA2g2a was induced in liver nearly
3.8 fold in response to a high fat diet (Figure 3-6B).
T3 Inhibits the Expression of PLA2g2a in C57BL/6 hPLA2gIIA+ Mice
In this experiment (Figure 3-7A-I), I tested the effect of hypo and
hyperthyroidism in C57BL/6 hPLA2gIIA+ mice. These C57BL/6 hPLA2gIIA+ mice
express human PLA2g2a. This experiment was important for demonstrating the
feasibility of the future mouse experiments where we propose to identify the role of
PLA2g2a in liver. As shown in Figure 3-7A hyperthyroid rats had significantly lower
levels of PLA2g2a. Similarly other sPLA2 isoforms (Figure 3-7B-D) excluding
PLA2g1b were inhibited in hyperthyroid rats. Negative control gene SREBP-1c (Figure
3-6E) was also inhibited while positive control genes were stimulated (Figure 3-7F-H)

39

Figure 3-4.

T3 inhibits the expression of PLA2g2a in vivo in rats

A) Rats were made hypothyroid with an iodine free diet and the addition of PTU. After 5
weeks, the animals were sacrificed and mRNA was harvested from the liver. The mRNA
levels were measured for A) PLA2g2a, B) PLA2g1b, C) PLA2g3, D) PLA2g5, E)
SREBP-1c, F) PDK4, G) PEPCK, H) CPT1a. I) PLA2g2a protein abundance was
measured by western blotting. Values are the average of RNA from 4 rats. The data are
expressed as the mean of the fold change by PTU+T3 ± S.E.M of mRNA abundance
relative to PTU treated rats (** = p value <0.01; *** = p value <0.001).
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Figure 3-5.

T3 regulates PLA2g2a in BALB/c mice

A) BALB/c mice were made hypothyroid as mentioned previously. Hyperthyroidism was
induced by injecting them with a lower dose of T3 (0.11mg/kg body wt.) for two days.
Mice were sacrificed and liver were harvested for RNA. The mRNA levels were
measured for A) PLA2g2a, B) PDK4, C) PEPCK D) CPT1a. Values are the average of
RNA from 5 mice. The data are expressed as the mean of the fold induction by PTU+T3 ±
S.E.M of mRNA abundance relative to PTU treated mice (** = p value <0.01; *** = p
value <0.001).
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Figure 3-6.

PLA2g2a is induced by high fat diet and hypothyroidism

A) Primary rat hepatocytes were treated with 100 nM T3 or oleic acid (18:1) or both.
Cells were harvested and PLA2g2a was measured. B) BALB/c mice were kept on chow
diet, iodine deficient PTU diet and high fat diet for 12 weeks. Mice were sacrificed after
12 weeks and liver was harvested for mRNA analysis. The levels of PLA2g2a were
measured by RT-PCR.
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Figure 3-7.

T3 inhibits sPLA2s in transgenic C57BL/6 hPLA2gIIA+ mice models

C57BL/6 hPLA2gIIA+ mice were kept on iodine free and PTU supplemented diet for 5
weeks. After 5 weeks, the mice were sacrificed and mRNA was harvested from the liver.
The mRNA levels were measured for A) PLA2g2a, B) PLA2g1b, C) PLA2g3, D)
PLA2g5, E) SREBP-1c; F) PEPCK, G) PDK4, and H) CPT-1a, I) PLA2g2a protein
abundance was measured by western blotting. Values are the average of RNA from 7
mice. The data are expressed as the mean of the fold induction by PTU+T3 ± S.E.M of
mRNA abundance relative to PTU treated mice. (* = p value < 0.05; ** = p value <0.01;
*** = p value <0.001).
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T3. The abundance of the PLA2g2a protein was decreased by T3 administration (Figure
3-7I). The serum profile of hypo and hyperthyroid C57BL/6 hPLA2gIIA+ mice is shown
in Table 3-2. Serum levels of free unbound T3 (FT3), cholesterol (CHL), triglycerides
(TGS), high density lipoproteins (HDL) and low density lipoproteins (LDL) were
measured.
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Table 3-2.

Serum profiles of C57BL/6 hPLA2gIIA+ mice

Mice
PTU Mice 1
PTU Mice 2
PTU Mice 3
PTU Mice 4
PTU Mice 5
PTU Mice 6
PTU Mice 7
PTU+T3 Mice 1
PTU+T3 Mice 2
PTU+T3 Mice 3
PTU+T3 Mice 4
PTU+T3 Mice 5
PTU+T3 Mice 6
PTU+T3 Mice 7

CHL
(mg/dl)
145
188
152
131
174
166
157
41
47
53
37
23
53
30

TGs
(mg/dl)
48
43
60
49
59
59
69
36
55
52
55
22
38
42
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HDL
(mg/dl)
85
104
89
85
98
99
96
30
38
44
27
17
40
23

LDL
(mg/dl)
52
75
51
36
64
55
47
4
0
0
0
1.5
5
0

FT3
(pg/ml)
1.1
<1
1.8
3.3
1.5
1.3
1.1
14.3
18.3
24
16.4
20
17
20.1

CHAPTER 4. NUCLEAR COREPRESSORS MEDIATED THE INHIBITION
OF PLA2G2A GENE TRANSCRIPTION BY THYROID HORMONE*
Introduction
The genomic mechanisms by which T3 induces gene expression include the ligand
mediated activation of TRβ, the dissociation of corepressors and subsequent recruitment
of coactivators (Cheng et al, 2010b). Although, many genes are repressed by T3 the
mechanisms by which T3 represses gene expression are not as well understood. Several
hypotheses have been proposed to explain the TR mediated gene repression (Santos et al,
2011; Weitzel, 2008). However despite considerable effort, no consensus model has been
proposed. In this chapter I had investigated the mechanism of PLA2g2a repression by
thyroid hormone.
Material and Methods
Cloning of Rat PLA2g2a Promoter
Genomic DNA was isolated from a rat tail using Qiagen genomic DNA isolation
kit (51304). The rat PLA2g2a promoter region was obtained from the PCR amplification
of the genomic DNA. The forward primers contain Sac I restriction sites while and the
reverse primers contain a Bgl II restriction sites. The PCR products were cut with
appropriate restriction enzymes and were cloned into PGL4 expression vector. The
primers used to amplify the PLA2g2a promoter are listed in Table 4-1.
Transient Transfections of Luciferase Vectors
HepG2 cells were seeded 4 hours prior to transfections and were maintained in
DMEM media supplemented with 5% FBS, 5% BS and 1% penicillin and streptomycin.
The cells were than transfected by calcium phosphate method. Transfections included 2
µg of PLA2g2a luciferase reporters, 1 µg of SV40-TRβ and 0.1 µg of TK-renilla. On the
next day, cells were washed twice with phosphate-buffered saline (PBS) and the media
was changed to serum free DMEM media and 100 nM of T3 added. Cells were harvested
after 24 h of treatment in passive lysis buffer. Luciferase assays were conducted from the
cell lysate using the Promega Dual Luciferase kit (Cat No. E1960). Protein content in
each lysate was determined by BCA method. Luciferase values were normalized for
protein content and renilla luciferase activity to account for cell density and transfection
efficiency, respectively.
* Adapted with permission. Sharma P, Thakran S, Deng X, Elam MB, Park EA. (2013).
Nuclear Corepressors Mediate the Repression of Phospholipase A2 Group IIa Gene
Transcription by Thyroid Hormone J. Biol Chem, 2013 June 7; 288(23):16321-33.
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Table 4-1.
Nucleotides
-448 F.P
-378 F.P
-297 F.P
-203 F.P
-175 F.P
-119 F.P
-49 F.P
-24 F.P
+58 R.P

List of primers used for cloning PLA2g2a promoter
Primer sequence 5’ to 3’
AGTGAGCTCATGAATGACTGACACGTGAATTAAG
AGTGAGCTCACACTCATTCCCTCCCCTGT
AGTGAGCTCTGGGCTTTTGGAAAGTTCTC
AGTGAGCTCACCCATGGTATGAGGGCTTT
AGTGAGCTCTCAAGGCTGTTCTGCCAGCTGTT
AGTGAGCTCGTATGCCCGTCTGTGAATCC
AGTGAGCTCCCCTGCAGAGGGAAGAGCTATTTA
AGTGAGCTCGAGCATTGGGAGTACATGCCCA
AGTAGATCTTGGGCATGTACCTCTTGGAT
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Real Time PCR
RNA was isolated from primary rat hepatocytes using RNA-Stat-60 (Tel-Test).
Isolated RNA was then purified with the Qiagen RNeasy Mini Kit (74104). The
concentration of each sample was then measured by using the Nanodrop machine. For
RT-PCR, 2.5 µg of cDNA was prepared using Superscript III (Invitrogen) from the RNA
samples. The resulting cDNA was diluted 1:6 in nuclease free water for real time PCR
reactions. The parameters for real time PCR were as follows: 95°C for 5 min, 40 cycles
of 95°C for 15 s, 60°C for 30 s and 72°C for 10 s. Primers were used at a final
concentration of 0.1 μM. The target genes were normalized with the 18S gene.
Quantification of the PCR products was carried out using ΔΔCt method. The forward and
reverse primers used for real time PCR are provided in Table 4-2.
ELISA
HepG2 cells were grown in 24 well plates at a density of 0.2×106 cells/well. The
growth media consists of 5% FBS and 5% BS and 1% antibiotics penicillin and
streptomycin. Next day cells were washed twice with 1XPBS and were kept on serum
free DMEM was media. Cells were then given the desired treatments. After 18 hours of
treatment, cell culture media was collected in eppendorf tubes and centrifuged at 1200
rpm to remove any cell debris. The ELISA was performed on the supernatant cell culture
media for PLA2g2a (human Type IIA) using EIA Kit from Cayman chemicals (585000).
Electrophoretic Mobility Shift Assay
To conduct electrophoretic mobility shift assays, double-stranded
oligonucleotides were labeled with klenow enzyme and [α-32P] dCTP. Oligonucleotides
were designed to contain sequences representing the nTRE. Recombinant histidine
tagged TRβ (His-TRβ) and RXRα were prepared in the BL21 E. coli strain as described
previously (Jansen et al, 2000). The protein-DNA binding mixtures contained labeled
probe (60,000 cpm) in 80 mM KCl, 25 mM Tris-HCl (pH 7.4), 0.1 mM EDTA, 1 mM
dithiothreitol, 10% glycerol and polydeoxyinosine-deoxycytidine (dI-dC). In the
supershift assays antibodies were added prior to the addition of nuclear proteins. TRβ
supershift antibody was purchased from santa cruz. The binding reactions were incubated
at room temperature for 20 min and then resolved on 5% non-denaturing acrylamide gels
(80:1 acrylamide/bisacrylamide) in Tris-glycine running buffer (22 mM Tris and 190 mM
glycine) (Jansen et al, 2000). The electrophoresis was then carried out 160 volts for 70
minutes.
Site-Directed Mutagenesis of the PLA2g2a Promoter
The Quick-change-XL site directed mutagenesis kit (Agilent Technologies, Santa
Clara, CA) was used to alter nucleotides in nTRE in the -448/+58 PLA2g2a-luciferase.
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Table 4-2.

List of RT-PCR primers

Nucleotides
Rat PLA2g2a F
Rat PLA2g2a R
Rat PLA2g1b qiagen.
Rat 18 S F
Rat 18 S R
Rat FASN F
Rat FASN R
Rat SREBP-1c F
Rat SREBP-1c R
Rat PDK4 F
Rat PDK4 R
Rat CPT-1a F
Rat CPT-1a R
PLA2g2a RT-PCR F
PLA2g2a RT-PCR R
Hu PLA2g1b qiagen
Hu CPT1-a F
Hu CPT1-a R
Hu PEPCK F
HU PEPCK R
Hu FASN F
Hu FASN R
Hu PDK4 F
Hu PDK4 R

Primer sequence 5’ to 3’
CATGGCCTTTGGCTCAATTCAGGT
ACAGTCATGAGTCACACAGCACCA
QT00179529
CGGCTACCACATCCAAGGAA
TTTTCGTCACTACCTCCCCG
TGGAGAAGCCCAGGAACAACTCAT
ACCGAGTAATGCCGTTCAGTTCCT
CATGGATTGCACATTTGAAGAC
GCAGGAGAAGAGAAGCTCTCAG
GGATTACTGACCGCCTCTTTAGTT
GCATTCCGTGAATTGTCCATC
CGGTTCAAGAATGGCATCATC
TCACACCCACCACCACGAT
CATGGCCTTTGGCTCAATTCAGGT
AGGCTGGAAATCTGCTGGATGTCT
QT00000637
TGGCGTCTGAGAAGCATCAGCATA
ACACCACGTAAAGGCAGAAGAGGT
ATGTCAACTGGTTCCGGAAGGACA
TTTCAGGTTCAGGGCATCCTCCTT
AGGTTTGATGCCTCCTTCTTCGGA
TGGCTTCATAGGTGACTTCCAGCA
ACAGAGCCTGATGGATTTGGTGGA
TGACTGGGTCAACTGTACAGGCAT
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The forward (FP) and reverse primers (RP) used to introduce these mutations are shown
in Table 4-3.
siRNA Knockdown Experiment
Small interfering RNA (siRNA) against human SMRT and NCoR1 and RNA
interference-negative control were purchased from Dharmacon. HepG2 cells were grown
in 60mm plates and were transfected with the siRNA against SMRT, NCoR1 or
nonspecific RNA (200 pmol) using Lipofectamine 2000 (Invitrogen). Knockdown of
SMRT and NCoR1 was confirmed by real-time PCR and western blot. After 16 hours of
transfection, cells were treated with 250 nM T3 in serum free medium for 24 h. Fortyeight hours after transfection, cells were harvested for RNA and proteins.
Western Blot Analysis
Western blot analysis was performed on whole cell extracts from HepG2 cells and
rat hepatocytes (Attia et al, 2011). Cells were harvested in RIPA buffer (50 mM TrisHCl, pH 7.4, 100 mM NaCl, 5 mM EDTA pH 8.0, 1% Triton, 1 mM benzamidine, 0.5
mM PMSF and protease inhibitor mixture from Sigma). The cells were kept on ice for 30
minutes. Cell debris was removed by centrifugation at 12,000 rpm for 20 min at 4°C.
Protein was quantified by the BCA method. An equal amount of protein was loaded on a
3-8% Tris-acetate acrylamide gel and transferred to a 0.45-µm nitrocellulose membrane
(Bio-Rad). The membranes were immunoblotted with primary antibodies NCoR1 (5948,
Cell Signaling), SMRT (06-891, Millipore) and Actin (A3853, Sigma) in Tris buffered
saline with Tween 20 containing 5% nonfat dry milk powder. Membranes were incubated
with horseradish peroxidase-conjugated anti-rabbit secondary antibody. Immunoreactive
proteins were detected using Supersignal West Femto Chemiluminescent Substrate
(Thermo Scientific).
Immobilized Template Assay
To characterize the binding of TRβ to the PLA2g2a promoter region immobilized
template assays were carried out. PLA2g2a promoter fragments corresponding to regions
-119/+58 and the +1108 to +1256 control region were PCR amplified from genomic
DNA using the 5’ biotinylated forward primer and the reverse primers. The PCR
products were purified with a gel extraction kit (Qiagen, M-280). Streptavidin coated
Dynabeads (Invitrogen) were resuspended in equilibration buffer (5 mM Tris-HCl (pH
7.5), 1mM EDTA, 1M NaCl) and then conjugated with 70 ng biotinylated template for 30
min at room temperature with constant agitation The immobilized templates were
concentrated with a magnetic particle concentrator, washed once with 5 mM Tris-HCl,
pH 7.5, 1mM EDTA, 1M NaCl, 0.05% Tween 20 and subsequently with binding buffer
(20 mM HEPES (pH 7.6), 4 mM MgCl2, 80 mM KCl, 0.08 mM EDTA, 8 mM DTT, 10%
glycerol, and 0.05% Tween 20). The beads were concentrated by a magnetic particle
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Table 4-3.
Mutants
-102mut F
-102mut R
-97mut F
-97mut R
-92mut F
-92mut R
-87mut F
-87mut R
-82mut F
-82mut R

List site directed mutagenesis primers
Primer sequence 5’ to 3’
CCGTCTGTGAATCCATGCGCAGGCCACACCCACCT
CC
GTGGGTGTGGCCAAATAACATCTTCACAGACGGGC
ATAC
CCGTCTGTGAATCCATGCGCAGGCCACACCCACCT
CC
GGAGGTGGGTGTGGCCTGCGCATGGATTCACAGAC
GG
CGTCTGTGAATCCATTATTTTATAGCACCCACCTCC
CCATCCCTG
CAGGGATGGGGAGGTGGGTGCTATAAAATAATGG
ATTCACAGACG
GTGAATCCATTATTTGGCCAAGATAACCTCCCCAT
CCCTGTGGC
GCCACAGGGATGGGGAGGTTATCTTGGCCAAATAA
TGGATTCAC
CATTATTTGGCCACACCCTATGTCCCATCCCTGTGG
CTCTC
GAGAGCCACAGGGATGGGACATAGGGTGTGGCCA
AATAATG
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concentrator and resuspended in 25µl of binding buffer along with TRβ, RXRα, poly
deoxyinosine-deoxycytidine (dI-dC) and 100 nM T3 for 20 min at room temperature. The
Dynabeads were washed four times with binding buffer, resuspended in 3 X SDS-loading
buffers, resolved by 4-12% bis-tris gel and analyzed via immunoblotting. The primers
used for immobilized template assay are listed in Table 4-4.
Chromatin Immunoprecipitation Assays
ChIP assays were conducted according to manufacturer’s protocol for the
Millipore Magna ChIP kit (17-610) with minor modifications. Rat hepatocytes were
grown in RPMI 1640 media containing 5% fetal bovine serum and 5% calf serum for 24
hrs. Cells were treated with 100 nM T3 overnight in serum-free media. Next day cells
were cross linked with 1% formaldehyde for 10 min at room temperature and sonicated
as previously described (Attia et al, 2011) to give DNA fragments between 500-800bp.
The supernatant chromatin was precleared and immunoprecipitated with the control
antibody IgG (sc-2027, Santa Cruz), anti-TRβ (MA1-216, Thermo Scientific), antiNCoR1 (5948, Cell Signaling) or anti-SMRT (17-10057, Millipore) overnight at 4ºC
along with magnetic protein G beads. The beads were washed and the DNA eluted.
Eluted DNA was purified using the PCR purification kit (Qiagen 28104). DNA was
subjected to 32 cycles of PCR using 3-5 µL of DNA. PCR products were analyzed on 2%
Nusieve 3:1 agarose (Lonza, Walkersville, MD) and visualized with Multimage Light
Cabinet with Alpha Imager EP software. The primers used to amplify portions of the
PLA2g2a promoter are provided in Table 4-5.
Results
T3 Inhibits PLA2g2a at Promoter Level
To determine if T3 directly regulates PLA2g2a gene expression, the rat PLA2g2a
promoter was cloned and fused to the luciferase (luc) reporter. The -448/+58 PLA2g2aluc vector was transfected into HepG2 cells along with TRβ using the transient
transfection method. HepG2 cells were then treated with T3 for 24 hrs. T3 decreased the
activity of -448/+58 PLA2g2a-luc nearly by 70%. This result suggests that PLA2g2a is
regulated by T3 at promoter level and T3 inhibits PLA2g2a expression by inhibiting its
transcription. Various conflicting reports have been published on the requirement of
DNA binding domain (DBD) for gene repression (Shibusawa et al, 2003). To evaluate
the role of the TRβ DBD, I made a TRβ mutant with only the ligand binding domain
(TRβ-LBD) and lacking DBD. TRβ-LBD was transfected with -448/+58 PLA2g2a-luc
into the HepG2 cells. Unlike full length TRβ, unliganded TRβ-LBD failed to exhibit the
T3 mediated repression (Figure 4-1). These data suggest that the intact DNA binding
domain is critical for T3 effect and TRβ might bind directly to PLA2g2a gene promoter.
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Table 4-4.

List of primers used for immobilized template assay

Nucleotides
-119PLA2g2a F
+58 PLA2g2a R
+1158 PLA2g2a F
1256 PLA2g2a R

Table 4-5.

Primer sequence 5’ to 3’
GTATGCCCGTCTGTGAATCC
TGGGCATGTACCTCTTGGAT
GCTATGGCTTCTACGGTTGC
CGGTGGGACACTGAGGTAGT

List of primers used for ChIP assay

Nucleotides
-180 rat PLA2g2aF
+61 rat PLA2g2a R
+1639 rat PLA2g2a F
+1900 rat PLA2g2a R

Primer sequence 5’ to 3’
GCCCGTCTGTGAATCCATTATTTGGC
CAAATGCATCCAAAGGGCAGGAGT
CACACACATGCATGCTGGGAACTT
GCTTAGGCTGCCTTTGAGTTCTCT
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Figure 4-1.

T3 inhibits PLA2g2a at promoter level

HepG2 cells were transfected with 2 µg of -448/+58 PLA2g2a luciferase, 1 µg of SV40TRβ or TRβ-LBD and 0.1 µg of TK-renilla and treated with or without T3 for 24 hours.
The data are expressed as the relative luciferase activity. Luciferase activity was
corrected for both protein content and Renilla activity. All experiments were repeated 3
to 4 times. The error bar indicates S.E.M. Significance is calculated relative wild TRβ
treated with T3 (*** = p value <0.001).
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Localization of a T3 Responsive Element in the PLA2g2a Gene Promoter
The next experiments were designed to identify the thyroid response element in
the PLA2g2a promoter. A series of deletions of the PLA2g2a gene were made between 448 and -24 region. The serial deletion removed approximately 20 to 80 bp fragments
from the 5’ end of the promoter in the -448/+58 PLA2g2a-luc vector. The diagrammatic
representation of 5’ serial deletions of PLA2g2a is shown in Figure 4-2A. These
PLA2g2a-luc constructs were then transfected into HepG2 cells and luciferase assays
were conducted. The luciferase activity of serial deletion was compared to the -448/+58
construct. The results are expressed in terms of percent inhibition. Deletion of the
promoter region between -102/-82 resulted in loss of repression by T3, suggesting that a
negative thyroid response element (nTRE) was located in the -102/-82 region proximal
promoter region (Figure 4-2B).
TRβ Binds Directly to the Proximal Promoter Region of PLA2g2a
Since the TRβ mutant lacking the DBD was not able to inhibit PLA2g2a-luc the
DNA binding domain of TRβ was required to represses PLA2g2a. We next tested
whether TRβ binds directly to the PLA2g2a promoter using immobilized template assays.
I generated a biotinylated -119/+58 fragment of the PLA2g2a promoter and a control
+1108/+1256 region. The biotinylated DNA templates were incubated with the
recombinant TRβ and RXRα with and without T3. The biotinylated templates along with
the bound proteins were precipitated by streptavidin beads. The beads were washed and
the bound proteins were eluted and analyzed by western analysis. TRβ bound as a
heterodimer with RXRα to the -119/+58 region, and T3 had no effect on the binding. In
contrast, no binding was observed in control +1108/+1256 region (Figure 4-3).
Characterization of the nTRE in the PLA2g2a Promoter
Next, I examined whether TRβ binds directly to the nTRE (-102/-82) of the
PLA2g2a gene. Electrophoretic mobility shift experiments were performed using purified
recombinant TRβ or RXRα proteins. Binding studies were carried out with a 32P labeled
PLA2g2a nTRE oligomer. The DNA/protein complexes were resolved on a nondenaturing acrylamide gel. The results showed that neither TRβ nor RXRα alone could
bind to the -102/-82 region (Figure 4-4A lanes 2 and 3). TRβ along with RXRα bound as
a heterodimer to -102/-82 region while T3 had no effect on binding (Figure 4-4A lanes 4
and 5). To confirm the specificity of the protein binding, antibodies to TRβ and IgG were
used. The TRβ antibody disrupted the complex showing that TRβ was present in the
complex (Figure 4-4A lane 6), whereas a nonspecific antibody had no effect (Figure
4-4A lane 7). To check the specificity of the sequence, competition assays were
conducted using a 10-fold excess of double-stranded unlabeled -102/-82 oligomer, an
idealized TRE (DR4) or a nonspecific unlabeled oligomer. The unlabeled -102/-82
oligomer competed with the TRβ binding (Figure 4-4B lane 3) and the DR4 completely
disrupted binding while nonspecific oligomers had no effect (Figure 4-4B lanes 4 and 5).
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Figure 4-2.

Localization of thyroid response element

A) A model of the serial deletions of the rat PLA2g2a promoter ligated in front of the
luciferase reporter gene (PLA2g2a-luc) is shown. B) HepG2 cells were transfected with
various 5' serial deletions of PLA2g2a-luc and an expression vector for TRβ. Cells were
treated with T3 for 24 hours. The data are expressed as relative inhibition with T3. All
transfections were repeated 4 to 6 times. The significance is calculated relative to the
empty vector PGL4. The error bar indicates S.E.M (* = p value < 0.05; ** = p value <
0.01; *** = p value <0.001).
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Figure 4-3.

TRβ binds directly to the proximal promoter region of PLA2g2a

A) Schematic representation of PLA2g2a core promoter primers and control primers used
to generate biotinylated DNA. B) The immobilized template assay was conducted with
the biotinylated DNA corresponding to region -119/+58 and +1158/+1256 control region.
The biotinylated DNA was incubated with His-TRβ and His-RXRα with and without T3.
The protein DNA complexes were resolved on Bis-Tris 4-12% gel and probed for TRβ by
western blotting.
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Figure 4-4.

Characterization of negative thyroid response element

A) Double-stranded oligonucleotides were constructed that encompassed the -102/-82
nucleotides in the PLA2g2a gene. The 32P-radiolabeled double-stranded oligomer
representing the -102/-82 element was incubated with purified recombinant TRβ and
RXRα. Antibodies to TRβ and IgG as well as 100 nM of T3 were added. B) To assess the
specificity of the TR-RXRα binding, a 10-fold excess of the competitor oligomers was
added. Competition assays were conducted using double-stranded unlabeled -102/-82
direct repeat of AGGTCA separated by 4 nucleotides (DR4) and nonspecific oligomer
(NS).
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The DR4 oligomer competed more strongly than the self -102/-82 oligomer suggesting
that the TRβ/RXRα heterodimer had more affinity for DR4 as compared to nTRE.
nTRE by Itself Conferred T3 Responsiveness
To determine if the nTRE conferred T3 responsiveness to a neutral promoter, I
ligated two copies of the nTRE (-102/-82) element in front of SV40-luciferase. This 102/-82 PLA2g2a- SV40 luc along with TRβ and TK-renilla was transfected into HepG2
cells. The nTRE PLA2g2a- SV40 luc reporter was efficiently repressed in the presence of
T3. As shown in Figure 4-5, T3 does not have any effect on empty SV40-lucierase, while
on -102/-82 SV40-Luc was inhibited nearly 60%. These data showed that the nTRE could
repress transcription in the absence of other proteins associated with the PLA2g2a
promoter.
TRE-Like Half Site GGCCA is Critical for Regulation of PLA2g2a by T3
For identification of the exact nucleotides critical for TRβ/RXRα binding, I made
mutations in the nTRE. Five different mutants having five base pair mutations in the 102/-82 region were designed and named as -102 mut, -97 mut, -92 mut, -87 mut and -82
mut. Competition analyses were conducted using these mutants. The different mutant
sequences are shown in Figure 4-6A. The DNA protein complex was competed by a 10fold excess unlabeled wild type -102 /-82 regions (Figure 4-6B lane 3). Mutant -97, -92
and -82 were unable to compete (Figure 4-6B lanes 5, 6 and 8) while mutants -102 and 87 competed (Figure 4-6B lanes 4 and 7). These data indicate that the nucleotides within
the -97/-93, -92/-88 and -82/-79 nucleotides are involved in TRβ/RXRα binding. Each of
the mutations was introduced into the -448/+58 PLA2g2a-luc and transfected into HepG2
cells. The -92/-88 mutation eliminated the ability of unliganded TRβ to induce PLA2g2a
and blocked the inhibition by T3 (Figure 4-7). These data demonstrate that there is an
nTRE in the promoter of the PLA2g2a gene and the single TRE-like half site GGCCA is
critical for regulation of PLA2g2a by T3.
I also tested whether the nTRE was required for the T3 inhibition of the TNF
induction of PLA2g2a. The TNF stimulation of PLA2g2a-luc was reduced by T3, but
expression of the PLA2g2a-luc vector with the disrupted nTRE (mut-92) was not blocked
by T3 indicating that T3 inhibits cytokine action through this element (Figure 4-8).
Coactivators Participate in Unliganded TRβ Mediated Induction of PLA2g2a
Unlike positively regulated genes, some studies on negatively regulated genes
have suggested that the unliganded TRβ instead of being inhibitory is stimulatory
(Furumoto et al, 2005; Liu et al, 2011). To order to determine if unliganded TRβ could
stimulate the PLA2g2a gene, I transfected SV40-TRβ with PLA2g2a-luc. In the absence
of ligand I observed that, TRβ stimulated the PLA2g2a promoter nearly 2.5 fold as
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Figure 4-5.

nTRE (-102/-82 region) by itself conferred T3 responsiveness

The -102/-82 element was cloned into a luciferase reporter plasmid in front of the SV40
promoter (-102/-82 SV40-luc). This reporter was cotransfected with TRβ into HepG2
cells in the presence or absence of T3. Cells were treated with T3 for 24 hrs. The
transfections were repeated four times. Luciferase activity was corrected for both protein
content and renilla activity. The error bar indicates S.E.M (** = p value < 0.01).
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Figure 4-6.

Characterization of the thyroid response element

Mutations in the -102/-82 element were made to identify the nucleotides necessary for
TRβ binding. A) The sequence of the various nucleotide substitutions is shown. B)
Competition gel shift assays were conducted with a 10-fold excess of unlabeled -102/-82
mutants and purified TRβ and RXRα proteins.
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Figure 4-7.

Identification of nucleotides critical for T3 responsiveness

A) Different mutants of the PLA2g2a promoter corresponding to the gel shift oligomer
sequences were introduced by site directed mutagenesis. HepG2 cells were transiently
transfected with 2 µg of different PLA2g2a luciferase mutants, 1 µg of SV40-TRβ and
0.1 µg of TK-renilla. Cells were treated with or without T3 for 24 hours. All transfections
were repeated 4 times. Luciferase activity was corrected for both protein content and
renilla activity. The error bar indicates S.E.M (* = p value < 0.05; ** = p value <0.01).

62

Figure 4-8.
PLA2g2a

nTRE was required for the T3 inhibition of the TNFα induction of

HepG2 cells were transfected with PLA2g2a-luc and treated with 25 ng/ml TNF or 100
nM T3. All transfections were repeated 4 times. Luciferase activity was corrected for both
protein content and renilla activity. The error bar indicates S.E.M (*** = p value <0.001).
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compared to the basal levels (Figure 4-9A).
I next investigated the effect of a constitutively active TRβ using the full length
TRβ fused to viral protein activation domain (TRβ-VP16). A DR4 containing reporter
was strongly induced by TRβ-VP16 (Figure 4-9B). PLA2g2a expression was markedly
reduced by TRβ-VP16 and reduction was unchanged by T3 (Figure 4-9C). These results
support the concept that the activated TRβ represses PLA2g2a. I hypothesized two
possible mechanisms that might be involved in PLA2g2a repression. The first possibility
was a role reversal mechanism where the function of coregulators is reversed so that the
coactivator causes gene repression while corepressors do the opposite. Another
possibility was the inverse recruitment of coregulators i.e. the coactivators is associated
with unliganded TRβ while T3 binding leads to corepressor recruitment. To understand
the role of coactivators in PLA2g2a regulation, TRβ was transfected with coactivator
CBP with and without T3. CBP increased the TRβ mediated induction of PLA2g2a and
had no effect on T3 dependent repression (Figure 4-9D). This suggested the possibility
that the inverse recruitment mechanism might account for T3 mediated regulation of
PLA2g2a.
TR β Mutant Defective in Corepressors Binding Leads to Loss of T3 Effect
I introduced previously characterized mutations (Collingwood et al, 1998;
Marimuthu et al, 2002b) in the hinge region of TRβ (mut214) to reduce the interactions
of TRβ with corepressors. Two other mutations in the AF-2 domain of TRβ, which were
defective in coactivator binding, were made (mut454 and mut457). T3 mediated
repression of PLA2g2a-luc was relieved 50% by the TRβ mut214. In contrast this
mutation had no effect on the T3 induction of the CPT-luc. Similarly, mutations in the
AF-2 domain (TRβ mut454) decrease the positive actions of T3 on CPT-luc and had no
effect on T3 mediated repression of -448/+58 PLA2g2a-luc. Surprisingly, the TRβ
mut457 did not repress PLA2g2a (Figure 4-10A and 4-10B). The corepressors and
coactivators share some interactive surfaces within TRβ so that a single mutation could
decrease association of both classes of coregulators (Watson et al, 2012). Overall, these
data suggested that corepressors were involved in the inhibition of PLA2g2a by T3.
T3 Inhibition of PLA2g2a Requires Corepressors
To assess the role of corepressors in T3 mediated inhibition of PLA2g2a, I
knocked down NCoR1and SMRT in HepG2 cells by siRNA. Knockdown of both
corepressors was confirmed at the mRNA and protein levels (Figure 4-11A-D). Cells
were treated with T3. Knockdown of NCoR1 and SMRT reduced the ability of T3 to
inhibit PLA2g2a (Figure 4-12A and B). In contrast, T3 mediated induction of positively
regulated gene PEPCK was not affected by corepressor knockdown (Figure 4-12C). This
experiment suggests that corepressors participate in T3 mediated inhibition of PLA2g2a.
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Figure 4-9. Activated TRβ receptor represses PLA2g2a and coactivators
participate in the induction of PLA2g2a by unliganded TRβ
HepG2 cells were transiently transfected with 2 µg of PLA2g2a luciferase reporters, 1 µg
of null vector pSV-sport or SV40-TRβ and 0.1 µg of TK-renilla. T3 was added for 24
hours. B) HepG2 cells were transiently transfected with 2 µg of TRE X 2 SV40-luc
luciferase reporters, 1 µg of VP16-TRβ and 0.1 µg of TK-renilla. T3 was added for 24
hours. C) PLA2g2a-luc was tested with VP16-TR as above. D) HepG2 cells were
transfected with PLA2g2a-luc, SV40-TRβ or CBP. T3 was added for 24 hrs. The error
bars indicates S.E.M (* = p value < 0.05; ** = p value <0.01*** = p value <0.001).
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Figure 4-10. Corepressors participate in the T3 mediated inhibition of PLA2g2a
A) PLA2g2a was transfected with three different TRβ vectors carrying single amino acid
substitutions. B) -4495/+1240 CPT1a-luc was transfected with the same TRβ expression
vectors. The data are expressed as the relative luciferase activity. Luciferase activity was
corrected for both protein content and renilla activity. All experiments are repeated 3 to 4
times. The error bar indicates S.E.M. Significance is calculated relative to wild TRβ
treated with T3 (*** = p value <0.001).
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Figure 4-11. Knockdown of corepressors by siRNA
HepG2 cells were transfected with siNCoR1 and siSMRT or scrambled siRNA overnight.
A) The knockdown of NCoR1 mRNA was assessed by real time PCR. B) The
knockdown of SMRT RNA abundance was measured (*** = p value <0.001). The
protein abundance of C) NCoR1 and D) SMRT following knockdown is shown by
western blot analysis.
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Figure 4-12. Corepressors are involved in T3 mediated repression of PLA2g2a
HepG2 cells were transfected with siNCoR1 and siSMRT or scrambled siRNA overnight.
The following day cells were treated with 100 nM T3 for 24 hrs. A) The mRNA
abundance of PLA2g2a was measured. B) The protein abundance of PLA2g2a was
measured by ELISA. C) The mRNA levels of the PEPCK gene were measured. The data
are expressed as the relative expression ± S.E. of mRNA abundance of T3 and untreated
HepG2 cells (* = p value 0.01 to 0.05; ** = p value <0.01; *** = p value <0.001).
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Corepressors are Recruited to the PLA2g2a Gene by T3
Since corepressors were involved in T3 dependent repression of PLA2g2a, we
next asked whether corepressors are associated with the PLA2g2a gene. The
relativeposition of ChIP primers is shown in Figure 4-13A. I conducted ChIP assays with
antibodies to TRβ, NCoR1 and SMRT. For these experiments, I used rat hepatocytes
since I had identified an nTRE in the PLA2g2a gene. My data indicated that TRβ is
associated with the PLA2g2a promoter (Figure 4-13B) and that addition of T3 increased
the association of corepressors NCoR1 and SMRT with the PLA2g2a gene promoter
(Figure 4-13C and 13D). These data support my hypothesis that T3 suppresses PLA2g2a
gene expression in part by the recruitment of corepressors.
Corepressors are Required for the T3 Inhibition of Other Genes
Next, I tested whether NCoR1 or SMRT were needed for the T3 repression of
other genes by using siRNA mediated knockdown of these corepressors in HepG2 cells.
We evaluated the expression of the following 12 known T3 responsive genes by real time
PCR (Lin et al, 2013; Sadana et al, 2011): A kinase anchor protein 4 (AKAP-4), serpin
peptidase inhibitor member 2 (SERPINE), solute carrier family 2 member 1 (SLC2A1),
family with sequence similarity 46, member A (FAM46A), solute carrier family 26,
member 3 (SLC26A3), sorbin and SH3 domain containing 1 (SORBS1), CD24 molecule
(CD24), heparan sulfate 3-O-sulfotransferase 3A1 (HS3T3A1), KIAA1199 protein
(KIAA1199), solute carrier family 1 member 4 (SLCA4), secretagogin EF-hand calcium
binding protein (SCGN), serine/threonine kinase 17b (STK-17B). Of these T3 repressed
genes, five genes including AKAP-4, SERPINE, SLCA4, STK-17B and HST3A1 had
decreased T3 responsiveness with corepressor knockdown while others were still
inhibited by T3 as shown in Figure 4-14. These data suggest that for some genes
corepressors are involved in liganded TRβ mediated inhibition of gene expression while
different mechanisms might be involved in repression of other genes by T3.
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Figure 4-13. Corepressors are recruited to the PLA2g2a gene by T3
Hepatocytes were treated with T3 for 24 hrs. Cells were cross-linked and the DNA
sheared for chromatin immunoprecipitation assays. A) A model of the PLA2g2a
promoter and the location of the primers are shown. B) The TRβ antibody (TRβ-Ab) was
used for immunoprecipitation. PCR products for the proximal promoter and the third
intron are shown. C) ChIP experiments were conducted with an antibody to NCoR1 D)
ChIP experiments were carried out with a SMRT antibody.
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Figure 4-14. Corepressors participate in the T3 inhibition of several hepatic genes
HepG2 cells were treated with siNCoR1 or siSMRT. Cells were treated with 100 nM T3
for 24 hrs. The mRNA abundance was determined by real time PCR: A) AKAP-4, B)
SERPINE, C) S SLCA4, D) STK17-B, E) SLC26A3, F) HS3T3A1, G) FAM46A, H)
SLC2A1, I) KIAA1199, J) CD24, K) SCGN and L) SORBS1. The data are expressed as
the relative expression ± S.E. of mRNA abundance of T3 and untreated HepG2 cells (* =
p value 0.01 to 0.05; ** = p value <0.01; *** = p value <0.001).
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CHAPTER 5.

DISCUSSION

Chronic low-grade inflammation is associated with obesity and hypothyroidism
(Garces et al, 2010; Kvetny et al, 2004). Secretory phospholipases are involved in various
inflammatory diseases including arthritis and atherosclerosis (Murakami et al, 2011). The
regulation and role of PLA2g2a has been studied in vascular smooth muscle cells and
macrophages in relation to atherosclerosis. (Murakami et al, 2010). Since PLA2g2a
expression is elevated in various inflammatory states and hepatocytes actively secrete
PLA2g2a, I investigated the regulation of PLA2g2a in liver.
Modulation of PLA2g2a Gene Expression by Thyroid Hormone in Liver
In Chapter 3, I examined the regulation of PLA2g2a in liver by T3. There have
been a very limited number of reports linking T3 with the expression of sPLA2. One
group found that PLA2g2a expression in astrocytes was reduced by T3 (Thomas et al,
2000). They reported that in brain astrocyte cells (DITNC1) T3 decreased sPLA2 activity.
At a 10nM concentration of T3, there was an approximate 50% decrease in sPLA2
activity. In addition to T3, they tested a pharmacologically T3 related compound
CGS23425, which similarly inhibited the sPLA2 activity. Another study reported
decreased expression of PLA2g2a in hypophysectomized rats treated with T3 (Boone et
al, 2011). Microarray analysis of the RNA isolated from liver of hypophysectomized rats
treated with T3 showed a profound decreased in the PLA2g2a levels followed by T3
treatment.
In my studies, I characterized the regulation of PLA2g2a and other sPLA2
isoforms by T3 in liver. I found that T3 decreased both the mRNA and protein abundance
of PLA2g2a by 60% in primary rat hepatocytes. T3 similarly inhibited the expression of
PLA2g2a in human hepatoma cell lines (HepG2). I found that the thyroid status regulated
endogenous PLA2g2a gene expression. Hyperthyroid rats had significantly lower levels
of PLA2g2a as compared to hypothyroid at rats the both mRNA and proteins level. I
observed that other sPLA2 isoforms including PLA2g1b, PLA2g3 and PLA2g5 were also
inhibited in hyperthyroid rats. Similarly in BALB/c mice, hyperthyroidism negatively
regulated the expression of PLA2g2a as compared to hypothyroid mice. Furthermore, T3
reversed the cytokine mediated induction of PLA2g2a by 50%. In both primary rat
hepatocytes and HepG2 cells the TNF and IL-6 mediated induction of PLA2g2a was
inhibited by T3.
Recent studies using PLA2g2a inhibitors have suggested that inhibition of
PLA2g2a confers resistance to diet-induced obesity (Iyer et al, 2012). Inhibition of
PLA2g2a resulted in beneficial changes in hepatic metabolic gene expression including
the induction of peroxisome proliferator activated receptor coactivator (PGC-1α) and the
inhibition of SREBP-1c. However, most PLA2g2a inhibitors have activity against all
sPLA2 isoforms so the precise contribution of PLA2g2a cannot be defined. Knockout of
the PLA2g1b isoform ameliorated the effects of high fat diets in part through the
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decreased intestinal absorption of lipids (Huggins et al, 2002; Hui et al, 2009). Overall,
these studies suggest that the secretory PLA2 isoforms contribute to the pathology of
diet-induced obesity.
Nonalcoholic fatty liver disease (NAFLD) is a common form of liver disease. It is
characterized by accumulation of triglycerides and hepatic inflammation Several TRβ
selective agonists including GC-1 and KB2115 have been shown to lower cholesterol and
stimulate hepatic metabolism. I believe that T3 and TRβ agonists by the virtue of their
ability to inhibit sPLA2 and lipogenic genes like sterol receptor element binding protein
(SREBP-1c) as well as by inducing genes involved in fatty acid oxidation like carnitine
palmitoyltransferase 1a (CPT1a) possess potential as treatments for hepatic steatosis. I
postulate that TRβ ligands could reverse hepatic steatosis and will improve the metabolic
profile first by decreasing sPLA2 expression and the associated inflammatory response
and secondly by reducing lipotoxicity via the stimulation of hepatic fatty acid oxidation
and inhibition of lipogenesis.
Nuclear Corepressors Mediated the Inhibition of PLA2g2a Gene Transcription by
Thyroid Hormone
In Chapter 4, I explored the mechanism of inhibition of the PLA2g2a gene by
thyroid hormone. The genomic mechanisms by which T3 induces gene expression
include the ligand mediated activation of TRβ, the dissociation of corepressors and
subsequent recruitment of coactivators (Cheng et al, 2010b). Interestingly, T3 inhibits
many genes in liver. Different mechanisms have been proposed to explain the TR
mediated gene repression (Santos et al, 2011; Weitzel, 2008). However despite
considerable effort, no consensus model has been proposed.
The transrepression hypothesis suggests that the nuclear receptor does not bind
the gene promoter directly, but instead interferes with the function of transcription
factors. For example, T3 inhibits hepatic ANGPTL3 gene expression via interactions of
TRβ with HNF4 bound to the ANGPTL3 proximal promoter (Fugier et al, 2006). The
glucocorticoid receptor suppresses expression of numerous inflammatory genes via
interactions with NF-KB and fos/jun (Rhen & Cidlowski, 2005). However, T3 does not
inhibit PLA2g2a through either the NF-KB or C/EBPβ binding sites suggesting that
transrepression is not the mechanism by which T3 represses PLA2g2a. In addition, the
DBD of TRβ is required for transcriptional repression.
An alternate hypothesis suggests that TRβ binds to nTREs in gene promoters
repressed by T3 (Kim et al, 2005; Lin et al, 2000; Santos et al, 2006). The mouse SREBP1c gene is inhibited via a nTRE in the promoter that binds TRβ/RXRα (Hashimoto et al,
2006). The SREBP-1c nTRE contains a single AGGTCA-like motif but to date a
consensus motif for the nTRE does not exist. Z elements, which are DNA sequences
often close to transcription start sites, have been described as nTREs. A core sequence
sequence (CAAAG) has been delineated (Nygard et al, 2006; Nygard et al, 2003; Sasaki
et al, 1999) for few negatively regulated genes but this sequence is not found within the
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PLA2g2a nTRE. Negative TREs do not resemble a classical positive TRE consisting of
an AGGTCA motif separated by four nucleotides (DR4). The β amyloid precursor
protein exhibits a variation of the nTRE in that the nTRE overlaps with Sp1 binding site.
Binding of TRβ precludes binding of Sp1 thereby inhibiting Sp1 mediated induction
(Villa et al, 2004). To investigate the PLA2g2a repression, we cloned the rat PLA2g2a
promoter and identified a nTRE. I provided several lines of evidence that this nTRE
requires TRβ binding. First, TRβ and RXRα bind as heterodimers as shown by gel shift
assays and immobilized template assays. The TRβ mutant lacking DNA binding domain
had no effect on PLA2g2a transcription suggesting that the DNA binding domain is
critical for the T3 inhibition. The -102/-82 (nTRE) region was sufficient for the T3
mediated suppression of SV40-luc. Other evidence supporting association of TRβ with
this region of the promoter included ChIP assays and mutagenesis studies.
A role reversal model has been proposed for a few negatively regulated genes in
which a corepressor such as SMRT functions as an activator or reciprocally a coactivator
represses (Santos et al, 2011). It was reported that SMRT activated the TSHα via the
nTRE. (Berghagen et al, 2002). A TR, which had a defective corepressor binding surface,
was unable to activate a nTRE (Ortiga-Carvalho et al, 2005). In my studies, transfection
of coactivators CBP had no effect on T3 repression of PLA2g2a, instead it increased the
unliganded TRβ mediated induction of PLA2g2a. Also, disruption of the corepressor
binding site of TRβ decreased the T3 inhibition of PLA2g2a suggesting that role reversal
was not the mechanism by which T3 acted.
For genes that are induced by T3, the unliganded TRβ represses gene expression
via the recruitment of corepressors (Zhang & Lazar, 2000). The inverse recruitment
hypothesis proposes that the liganded TR recruits corepressors rather than coactivators.
This hypothesis is supported by a recent study of mice harboring a mutation in the
deacetylase domain of NCoR1 which was defective in interaction with HDAC3. In these
mice, positive T3 responsive genes which are normally inhibited by unliganded TR were
activated, while negatively T3 regulated genes like TSHα and deiodinase 2 were modestly
induced by T3 (You et al, 2010). This suggests that on some negatively regulated genes
liganded TR might be associated with NCoR1.
In my studies, I found that the unliganded TRβ stimulated PLA2g2a transcription
leading me to speculate that coactivators were involved in the unliganded TRβ mediated
induction of PLA2g2a, while corepressors were associated with the liganded TRβ on
PLA2g2a promoter. To validate my hypothesis, I knocked down NCoR1 and SMRT by
siRNA in T3 treated the cells. Knockdown of these corepressors alleviated the T3
inhibition of PLA2g2a while there was no effect on the T3 stimulation of the positively
regulated PEPCK gene. To extend my findings to other T3 mediated negatively regulated
genes I conducted additional experiments to determine whether other genes need NCoR1
or SMRT for transcriptional repression by T3. I analyzed the expression of 14 genes that
are known to be inhibited by T3. I found that for five of these genes the T3 mediated
suppression of gene expression was reduced by NCoR1 or SMRT knockdown. I found
that the effect of T3 was lost in the AKAP, STK-17B, SERPINE and SLCA4 genes
suggesting that T3 recruits corepressors to inhibit other genes. These data suggest that for
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some additional genes repressed by T3 require corepressors like NCoR1 or SMRT.
However, not all the T3 suppressed genes utilize NCoR1 or SMRT suggesting either
redundancy of the corepressors functions or that additional mechanism are involved.
Using ChIP assays, I discovered that NCoR1 and SMRT are recruited to
PLA2g2a gene promoter in a T3 dependent manner. The possible model of inhibition of
PLA2g2a by T3 is shown in Figure 5-1. I believe that corepressors are recruited to the
PLA2g2a gene in a ligand dependent manner while coactivators may be associated with
the unliganded receptor. The basis for this inverse recruitment of corepressors by the
liganded TRβ is not understood. One possible explanation is that the DNA sequence acts
as an allosteric modulator for TRβ and could govern its conformation and hence
determine its association with coregulators (Putcha & Fernandez, 2009). It has been
shown that the sequence of the binding site for the GR determines its transcriptional
activity (Meijsing et al, 2009). In conclusion, our results demonstrate that T3 regulates
PLA2g2a gene expression in vitro and in vivo in rat liver. The nTRE in the PLA2g2a
gene is sufficient for T3 mediated inhibition. Our data indicate that T3 represses PLA2g2a
gene by an inverse recruitment mechanism in which the liganded TRβ has corepressors
associated with it.
In conclusion, my study has enhanced understanding of the molecular
mechanisms of T3 action and provides a cellular mechanism by which T3 inhibits
PLA2g2a expression. I have identified a novel inverse recruitment mechanism in which
unliganded TRβ is stimulatory while liganded TRβ recruits corepressors to inhibit
PLA2g2a expression. In addition to PLA2g2a, I discovered other novel genes which
require corepressors for T3 mediated inhibition.
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Figure 5-1.

Possible model for T3 mediated repression of PLA2g2a
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APPENDIX. SUPPLEMENTAL DATA

Figure A-1.

Hepatic gene regulation by TRβ agonist KB2115

Rat hepatocytes were treated with 1µM KB2115 for 24 hrs. RNA was harvested and
assessed for PLA2g2a mRNA abundance by real time PCR. Experiments were repeated
3 times. (** = p value 0.001 to 0.01, *** = p value <0.001).
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Figure A-2.

Time course for PLA2g2a regulation by KB2115

Rat hepatocytes were treated with KB2115 for various times and PLA2g2a mRNA
abundance was measured. Experiment was repeated 3-4 times. The data is expressed as
the percent inhibition.
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Figure A-3.

Comparison of KB2115 and T3 mediated regulation of hepatic genes

HepG2 cells were treated with 100 nM of T3 or 1µM of KB2115 for 24 hrs. RNA was
harvested and assessed for various T3 responsive genes by real time PCR. Experiments
were repeated 4 times. (* = p value < 0.05; ** = p value <0.01; *** = p value <0.001).
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Figure A-4. Comparison of KB2115 and T3 mediated regulation of the regulation
sPLA2 isoforms in hepatocytes
HepG2 cells were treated with 100 nM of T3 or 1µM of KB2115 for 24 hrs. RNA was
harvested and assessed for mRNA abundance of sPLA2s was measured by real time
PCR.
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Figure A-5.

Effect of KB2115 on cytokines mediated induction of PLA2g2a

HepG2 cells were treated with 10 ng/mL IL-6 or 100 nM T3 or both for 24 hrs. PLA2g2a
mRNA abundance was assessed. B) Media was collected from HepG2 cells treated with
IL-6 or T3 and the PLA2g2a levels were determined by ELISA. All experiments were
repeated 3 times. The data are expressed as the mean of the fold induction ± S.E.M of
mRNA abundance relative to untreated control cells (* = p value < 0.05; ** = p value
<0.01; *** = p value <0.001).
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Figure A-6.

T3 and KB2115 decreases fatty acid mediated induction of PLA2g2a

Rat hepatocytes were treated with 100 nM T3, 1µM KB2115 or 100 nM of oleic acid for
24 hrs. PLA2g2a mRNA levels were measured by real time PCR.
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Figure A-7.
PLA2g2a

Identification of Sp1 binding to -102/-72 proximal promoter region

A biotinylated oligomer representing the sequence between-102/-72 was incubated with
rat liver nuclear extract. Antibody to Sp1 was added. The resulting complexes were
resolved on a 4-6% non-denaturing polyacrylamide gel.
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Figure A-8.

Binding of purified recombinant TRβ and RXRα. with DR-4

The double -stranded oligonucleotides corresponding to DR-4 were constructed and
labeled with the 32P. The-radiolabeled DR-4 was incubated with purified recombinant
TRβ and RXRα.
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Figure A-9.

CEBPβ induces the expression of PLA2g2a luciferase

HepG2 cells were transiently transfected with 2 µg of different PLA2g2a luciferase
mutants, 1 µg of SV40-TRβ, 1µg of MSV CEBPβ and 0.1 µg of TK-renilla. Cells were
treated with or without T3 for 24 hours. All transfections were repeated 4 times.
Luciferase activity was corrected for both protein content and renilla activity. The error
bar indicates S.E.M (* = p value < 0.05; ** = p value <0.01).
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Figure A-10. Inhibitor of steroid receptor coactivator-TRβ interactions represses
PLA2g2a gene expression
HepG2 cells were exposed to T3 (100 nM) or GB1210, the SRC recruitment inhibitor,
(1µM) for 24 h. The mRNA abundance of A) PLA2g2a, B) PEPCK was measured by
RT-PCR. All experiments are repeated 3 times (* = p value < 0.05, ** = p value 0.001 to
0.01, *** = p value <0.001).
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